U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Cover of Assessing Support for Medicine Decision Making for Youth with ADHD Who Receive Therapy

Assessing Support for Medicine Decision Making for Youth with ADHD Who Receive Therapy

, PhD, , PhD, and , PhD.

Author Information and Affiliations

Structured Abstract

Background:

For childhood attention-deficit/hyperactivity disorder (ADHD), treatments that combine behavioral and pharmacologic interventions have proven to be more efficacious than either behavioral treatment alone or medication alone. Despite the strong evidence base for these 2 treatment types, both remain vastly underused for a host of reasons. Further, combined treatment has not been systematically tested among adolescents. The issue is further compounded by a lack of understanding within the field about comorbidity issues related to substance use (SU) among adolescents with ADHD.

Objectives:

The primary objective of this cluster randomized trial was to compare the effectiveness of behavioral-only vs integrated (behavioral plus medication decision-making) interventions for adolescents with ADHD in outpatient services on participant functioning and service use. A secondary objective was to examine patient-centered outcomes with respect to heterogeneity of effects among adolescents with and without SU problems and individual differences in effects on participant functioning based on ADHD medication use.

Methods:

A cluster randomized intention-to-treat (ITT) longitudinal design was used to test the effects of behavioral-only vs integrated (behavioral plus medication decision-making) treatment in routine care for all adolescents who met diagnostic criteria for ADHD in 5 outpatient behavioral health clinics. In the behavioral-only condition, therapists were trained in an academic support intervention protocol for adolescents with ADHD focused on homework management and organizational training. In the integrated condition, in addition to academic support interventions, therapists were trained in a family-based medication decision-making protocol. Clinicians were randomly assigned to study condition in a 2:1 ratio favoring the integrated condition. Therapist fidelity to each treatment protocol was assessed via both therapist-report checklists and observation of session recordings. Primary outcomes were ADHD symptoms, comorbid problems, executive functioning, and school functioning. Secondary outcomes were treatment attendance, medication acceptance, and treatment satisfaction. Primary outcomes were analyzed using latent growth curve modeling to examine the impact of treatment condition on change over time in client outcomes. Secondary outcomes were tested via multistep heterogeneity of effects analyses focused on moderator effects.

Results:

The study enrolled 145 clients (n = 53 behavioral only, n = 92 integrated) treated by 49 therapists (n = 20 in behavioral only, n = 29 in integrated). Adolescent participants were 72% male; 42% White non-Hispanic, 37% Hispanic American, 15% African American, and 6% more than 1 race; and average age was 14.8 years. Therapist participants (N = 49) included 82% women; 63% White non-Hispanic, 29% Hispanic American, and 10% some other race/ethnicity; average postgraduate experience was 5.1 years. All enrolled clients and therapists were included in study analyses (ITT). Therapist self-reports of protocol adherence indicated strong treatment fidelity overall: Observer ratings indicated overall fidelity with regard to delivery of Changing Academic Support in the Home for Adolescents with ADHD (the behavioral protocol for boosting academic outcomes) but not with regard to medication integration protocol fidelity. Analysis of primary outcomes found that for most client outcomes, there were no meaningful differences between treatment conditions. Regarding ADHD symptoms, integrated care produced a greater decline in adolescent-reported ADHD inattentive symptoms. However, there were no differences for adolescent-reported hyperactive symptoms, caregiver-reported inattentive symptoms, or caregiver-reported hyperactive symptoms. Regarding comorbid problems, integrated care produced a greater decline in number of delinquent acts compared with behavioral-only care However, there were no between-group differences for adolescent-report internalizing symptoms, adolescent-report externalizing symptoms, caregiver-report internalizing symptoms, caregiver-report externalizing symptoms, or SU. No between-group differences were found for executive functioning (self-regulation, self-organization), school functioning (school grades, academic self-efficacy, homework problems, minutes spent doing homework), or medication use. Post hoc analyses identified some between-group differences between adolescents who did, vs did not, use substances at baseline. No intervention harms or other adverse events were reported.

Conclusions:

Significant additive effects for medication decision-making interventions were found for a minority of the main effects tested and for a minority of the subgroups of adolescents examined in post hoc analyses, across clinical, developmental, and medication outcomes.

Limitations:

The number of participating sites was too small to test for site effects. Participating therapists at each site were self-selected, creating some limitations to the generalizability of findings. The 2:1 randomization ratio was not purely achieved due to initially randomized therapists being excluded because they were never assigned a study case (n = 33), as well as the need to assign a small subset of therapists directly to the condition to maintain critical mass for group consultation. In the absence of a no-treatment control group, the magnitude of research assessment effects on client outcome cannot be estimated, although it is presumed to be equally distributed across conditions. Because multiple hypotheses were tested, there is an increased possibility that 1 or more reported analyses represents a chance finding.

Background

Attention-deficit/hyperactivity disorder (ADHD) exists in 20% to 50% of the 3 million adolescents annually enrolled in outpatient mental health and substance use (SU) treatment. Adolescents with ADHD present deficits in attention, self-regulation, and social competence that significantly impede achievement of developmental and educational milestones. Currently 2 treatment options have been described by some as meeting methodological criteria (although not universally recognized criteria, for which there is no canonical definition) for being well established1,2 for this age group: academic training (ie, homework management support and organizational skills training) and stimulant medications. Both options remain vastly underused. Supportive academic training is not available in most school settings and underused in clinical care. Similarly, ADHD medications are underused with adolescents in primary or specialty care for a host of reasons related to stigma, misinformation about effects and adverse effects, and adolescent autonomy issues. Another treatment option for adolescents with ADHD that has garnered some research support is cognitive-behavioral therapy, which includes coping skills training.

For ADHD among elementary-aged children, treatments that combine behavioral and pharmacologic interventions have generally (although not exclusively) proven to be more efficacious than either behavioral treatment alone or medication alone. Many current practitioner guidelines stipulate that medication is the first-line treatment option for youth, whereas others suggest that behavioral interventions should be the first option, with medication subsequently added only if behavioral-only treatment does not produce desired effects. The most rigorous longitudinal study of ADHD treatment to date found that the superiority of combined treatment during childhood years dissipated in adolescence, possibly due to medication desistance and/or stronger maintenance effects for behavioral interventions. Moreover, long-term medication use by itself does not appear to provide significant benefits to academic functioning. Thus, there are several compelling reasons to test medications combined with behavioral interventions during the teenage years. Yet combined treatment has only rarely been tested among adolescents, leaving many important issues about treatment choices and medication decision-making for teens unresolved.3-5

This study also examined comorbidity problems related to adolescent substance use (ASU). ADHD has even greater prevalence and morbidity for adolescents with co-occurring ASU. Estimates of ASU comorbidity among adolescents with ADHD in outpatient care range from 25% to 60%. Compared with teens without ADHD who use substances, those with ADHD tend to transition more quickly from SU to dependence, drop out of treatment earlier, have a worse symptom course and treatment outcomes, have worse mental health prognoses, and return to using substances in greater numbers and more rapidly after ASU treatment. These data raise a key question: Are ADHD medications a viable option for teens with ASU problems? A common concern among clinicians and families alike is that prescribed stimulants will exacerbate SU problems and/or create risk for misuse or diversion by teens who use substances. However, the best available evidence provides strong consensus that prescribed ADHD medications do not present additional risk for substance misuse or exacerbate ASU problems. Moreover, evidence is emerging that ADHD medication can have additive benefits when combined with behavioral treatment for adolescents with comorbid ADHD and ASU.6-8

This study was designed to help fill these gaps in the evidence base for adolescents with ADHD and co-occurring problems seeking outpatient behavioral treatment. This is among the first studies to test whether shared decision-making interventions affect medication uptake and improve behavioral outcomes for adolescents with ADHD enrolled in community-based behavioral services. Few evidence-based resources exist to guide clinicians in merging medication interventions into behavioral treatment planning for teens (Bukstein and Cornelius9). As a result, families in community-based services are often poorly informed about choices of available ADHD medications and the risk and benefits of each,10 especially when behavioral therapists themselves have insufficient knowledge about ADHD or harbor biases against psychiatric medication.11 Given this clinical context, family-based medication decision-making interventions, in which family attitudes about medication are systematically processed in the context of collaborative benefit-cost decisions about treating ADHD, are essential for facilitating family-centered decisions about medication use among teens.12 Broadly speaking, shared decision-making involves jointly deciding on a treatment plan that takes into account patients' preferences, needs, and values along with provider knowledge and experience.13-15 The science of shared decision-making in health care contexts has greatly matured in recent years,16-18 yielding this core set of effective ingredients: educating and exchanging information with patients about a health problem, identifying patient values and preferences, reviewing treatment options with an emphasis on risks/benefits, and agreeing on a treatment plan.18-20 For teens with ADHD, medication selection is directly related to caregiver beliefs about the causes of behavioral problems,10 and beliefs about ADHD in particular are mutable over time when families engage in shared decision-making with providers.12

The behavioral protocol for boosting academic outcomes developed during this study is Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA).21 The medication decision-making protocol for supporting family-based deliberations about ADHD medication use developed during this study is the medication integration protocol (MIP).22,23 CASH-AA was created for this study; MIP was previously created and tested in a small pilot study.22,23 A secondary objective was to examine patient-centered outcomes with respect to heterogeneity of effects among adolescents with and without ASU problems and individual differences in effects based on ADHD medication use.

The study is important for several reasons. It took place in existing behavioral health clinics to test frontline treatment effectiveness. Both protocols (CASH-AA and MIP) are evidence based, affording a rigorous test of the best available treatment options for this clinical group. The test has immediate real-world implications: Families enrolled in specialty treatment settings invariably prefer behavioral services only, but they need to know whether integrated medication interventions can provide a meaningful boost to outcomes that are most important to them. Ethnic minorities and girls with ADHD are both severely underserved and under-researched; the current study focused on urban minority teens, and about a quarter of the sample was female. Also, this study is among the first to test evidence-based ADHD treatment options for adolescents who use substances, another underserved and high-priority clinical risk group.

Aim 1: Comparative Impact on Client Functioning

Hypothesis 1: Reduced Symptoms

Integrated clients will show greater decreases in ADHD symptoms (inattention, hyperactivity/impulsivity) and comorbid problems (conduct and mood problems, SU) than will behavioral-only clients.

Hypothesis 2: Improved Quality of Life

Integrated clients will show greater improvements in executive functioning (self-regulation, self-organization) and school functioning (grades, self-efficacy, homework issues) than will behavioral-only clients.

Aim 2: Comparative Impact on Service Use

Hypothesis 3: Better Treatment Attendance

Integrated clients will attend more behavioral therapy sessions and medication management sessions than will behavioral-only clients.

Hypothesis 4: Greater Medication Acceptance and Treatment Satisfaction

Integrated clients will more often consent to medication, use medication to a greater degree, and report greater satisfaction than will behavioral-only participants.

Aim 3: Examine Patient-Centered Outcomes

Research Question 1: Heterogeneity of Treatment Effects

Will clients with co-occurring SU problems have worse treatment outcomes than those without? Will there be outcome differences based on age, ethnicity, and/or sex?

Research Question 2: Analysis of Individual Differences

Across treatment conditions, will clients who choose to start a medication regimen have better treatment outcomes than those who do not?

Participation of Patients and Other Stakeholders

This project relied on consultation from 5 stakeholder groups: (1) clinical researchers; (2) youth and family advocates (including school administrators); (3) clinical site administrators; (4) clinical site staff (behavioral therapists and physicians who volunteer to participate as study clinicians); and (5) former CASH-AA and MIP patients (caregivers and adolescents) who participated in pilot studies. This diverse stakeholder group offered a highly complementary set of perspectives, backgrounds, and technical skills with regard to ADHD clinical practice, clinical policy, treatment development and effectiveness research, treatment implementation and dissemination experience, client advocacy, and end-user decision-making. These stakeholder groups were involved in 3 types of meetings: (1) project launch meetings (3 total) aimed at informing and adjusting the proposed research and clinical procedures based on the multiple perspectives of all key stakeholders; (2) researcher meetings (convened semiannually) aimed at monitoring the integrity and progress of research procedures and data collection across sites; and (3) clinical stakeholder meetings (convened triannually) attended by therapists and supervisors at each partnering site aimed at providing corrective feedback on the ongoing implementation of study procedures and protocols as it pertained to engaging clients and staff in study activities.

Project Stakeholder Launch Meetings

First, to better understand the needs and viewpoints of families of adolescents with ADHD, the principal investigator (PI) met with 14 caregivers of adolescents with ADHD to discuss the various conceptual and strategic dimensions of patient-centered, family-based decision-making about ADHD medications for adolescents. This meeting was hosted in November 2014 by Children and Adults with Attention-Deficit/Hyperactivity Disorder, a national nonprofit that provides education, advocacy, and support for individuals with ADHD. This group voiced strong concerns that ADHD-related symptoms remained an impediment to optimal school performance for their children; that families needed much more information about the potential benefits, harms, and adverse effects of ADHD medications that pertain specifically to the teenage years; that they harbored significant reservations about the impact that stimulant medications might exert on SU vulnerability in their children, along with strong potential for misuse and diversion of prescribed medications; and that they welcomed guidance from professionals (pediatricians, school counselors, therapists) but did not feel that they could routinely access information about ADHD medication from sources other than the internet.

Second, before study materials were finalized, Drs Aaron Hogue and Steven Evans led a stakeholder meeting with 12 outpatient clinicians in February 2015, during which the clinical protocols were vetted. Feedback from this meeting provided expert user-centered insight into the design of study materials and training protocols. This group expressed a strong need for (1) standardized protocols that could be readily implemented in routine behavioral care but were flexible enough so that content could be tailored to meet the needs of a broad range of developmental and clinical profiles among adolescents and families; (2) user-friendly psychoeducation materials about ADHD medications for adolescents that covered the vast array of medical and behavioral concerns voiced by caregivers and teens, including concerns about providing medication to youth who use substances and/or have numerous SU risk factors, and that are easily understood and delivered by nonmedical providers; and (3) pragmatic behavioral interventions for boosting academic study habits of youth with ADHD, as well as corresponding guidance for caregivers on how to support their children effectively in this area, which is typically a source of substantial family conflict and parental stress.

Third, in March 2016, a larger executive stakeholder meeting was convened at the National Center on Addiction and Substance Abuse (now Center on Addiction) to present preliminary findings from year 1 of the project and to solicit feedback on the successes and challenges encountered during the first year. This meeting included a specific advisory group of 7 representatives from the research community, including the Child Mind Institute, ADD Resource Center, and Columbia University Medical Center; 8 representatives from one of our partnering treatment sites, ADHD educators, and national advocates; 4 representatives from youth-focused community agencies; and 3 youth and their families who had previously received services for ADHD that included early pilot versions of the 2 study protocols. This meeting provided an effective forum for discussing the need for psychoeducation for families of adolescents with ADHD, adolescent perceptions of medication use, and educators' roles in addressing ADHD in the classroom.

Semiannual Researcher Meetings

These meetings were attended by the PI, co-investigator (Dr Evans), and 2 senior clinical researchers who were independent of the study. The meetings reviewed the ongoing progress of site clinical training, family enrollment and home-based assessment, qualitative data collection, and quantitative data collection. These meetings yielded detailed procedures for improving study recruitment (eg, deploying research staff on site once per week at each partnering site to troubleshoot client identification and gain permission for initial research contact) and finalizing the design of qualitative data collection from study therapists.

Triannual Clinical Stakeholder Meetings

Every 4 months (triannually), 2 members of our research staff hosted a voluntary stakeholder meeting at each of the 5 enrolled treatment sites for therapists and supervisors to provide feedback on intervention and study procedures. These meetings were attended by about 6 to 8 therapists and 1 supervisor in each sitting at each site. Meeting goals included discussing therapists' use and implementation of the protocol, suggestions for protocol improvements, and methods to increase therapist and supervisor engagement in the study. Following stakeholder meetings, the research staff convened to discuss approaches to implement the stakeholders' feedback.

In the first triannual stakeholder meeting, supervisors from Outreach, one of our first treatment sites, reflected on their experiences with recruiting study participants, therapist training, and therapist use of the protocols. An essential piece of feedback the supervisors provided was that it would be useful to see summaries of the therapy procedures self-report form that the study therapists were submitting. In response, the research staff created monthly site-specific data reports and discussed them with therapists and supervisors during site fidelity meetings.

Before the August 2016 triannual stakeholder meeting, therapists had received feedback from research staff regarding compiled data from the therapist self-report checklist of treatment procedures used in sessions with study clients. After coding therapists' audio-recorded sessions and reviewing therapists' checklists, the research staff detected a pattern of therapists underrating their use of the CASH-AA module 1 intervention—specifically the motivational, reframing, and relabeling intervention—in the checklists. In response, during the August 2016 stakeholder meeting, therapists suggested that it would be helpful to receive more in-depth training in the module 1 intervention. As a result, the research team revamped the existing training materials for new sites and also conducted 1-hour CASH-AA module 1 trainings at already enrolled sites to help meet this therapist-identified need. Further, therapist feedback inspired the research staff to offer one-on-one protocol trainings upon request.

Other therapist-inspired additions included the creation of a weekly email bulletin and 5 one-page protocol review sheets. These were developed in response to therapist feedback that it was difficult to remember the protocols and cumbersome to quickly review the manuals while also gathering enough information to prepare and deliver the interventions successfully. As such, the weekly bulletins were created to provide brief (≤500 words) reviews of the different elements of the interventions. During subsequent triannual stakeholder meetings, therapists suggested that the bulletins had become a way to keep them updated on current ADHD research and other aspects of study progress also reported in the bulletins (eg, what interviews were like for the families, how many interviews had been completed, what rates of ADHD symptoms were reported at baseline by parents and teens). In addition, research staff created 5 one-page protocol review sheets: 2 briefly describing the CASH-AA and MIP interventions; 1 CASH-AA specific page describing how to adapt the protocol for teens who were no longer in school; 2 additional CASH-AA pages describing how to use the protocols for teens experiencing anxiety/depression; and 1 page for addressing family stress. The last 2 were developed as a direct response to feedback from therapists who were concerned that focusing solely on ADHD is not the most effective treatment strategy for teens struggling with various comorbidities. Taken together, these 5 one-pagers act as a quick reference guide to the protocols and offer ways to adapt the protocols to diverse adolescent mental health needs.

As the study continued, therapists expressed interest in receiving feedback on their session recordings and hearing about other clinicians' (eg, colleagues, supervisors, clinicians at other sites) implementations of the protocols with various types of clients and family structures, as well as across a variety of treatment settings (eg, family therapy clinics, SU clinics). Every month, a research staff member selected a 10-minute excerpt of a previously coded session recording that exemplified high-fidelity protocol delivery, and played the excerpt in monthly fidelity monitoring meetings. After a recording was played, research staff led a guided discussion addressing the strengths of the recorded session and alternative use of the protocols. As such, study therapists were able to reflect critically on both their own protocol implementation practices and those of their peers. This information was then incorporated into ongoing clinical consultation at each site.

Methods

Study Overview

The primary objective of this cluster randomized trial was to compare the effectiveness of behavioral-only vs integrated (behavioral plus medication decision-making) interventions for adolescents with ADHD in outpatient behavioral services. The behavioral intervention, CASH-AA, contains 3 components: family-based motivational interventions pertaining to ADHD and academic performance, academic skills training, and family-school partnership. The medication decision-making intervention, MIP, contains 3 components: education about ADHD and ADHD medication, family-based medication decision-making, and integrated medication management. The study aimed to (1) compare the effects of 2 evidence-based treatment options for adolescents with ADHD on behavior symptoms, quality of life (QOL), and service use (aims 1 and 2); and (2) generate new evidence on a patient-centered treatment provision that aligns with family-specific treatment goals (aim 3). We considered testing the 2 protocols in an efficacy trial, in which we could use narrow inclusion criteria to select a relatively homogeneous profile of cases and also selectively hire, train, and supervise research therapists delivering care in a controlled setting. In consultation with PCORI staff, we decided that testing the protocols in an effectiveness trial provided the greatest generalizability and overall benefit. We also carefully considered a research design in which integrated care (CASH-AA plus MIP) would be tested against a treatment-as-usual condition. Again in consultation with PCORI, we decided that testing integrated care (CASH-AA plus MIP) vs behavioral-only care (CASH-AA only) provided the most rigorous test of the unique effects of the family-based medication decision-making protocol (ie, MIP), which was deemed a top scientific priority for the discipline of patient-centered care.

Study Setting

All 5 partnering treatment sites were outpatient behavioral health clinics in the New York City metro area. There were 2 community-based mental health clinics, 1 hospital-based mental health clinic within a department of psychiatry, 1 community-based ASU clinic, and 1 community-based clinic co-licensed in mental health and SU services. All full-time therapists and clinical trainees at each site who treated adolescent clients and who volunteered to participate were accepted into the study; based on site administrator report, between 75% and 85% of therapists at each site volunteered, and this percentage did not vary significantly across sites. Therapists at each site managed comparable client caseloads (including individual, family, and group sessions), and each site routinely prescribed weekly treatment sessions and offered in-house psychiatric support. Therapists at each site routinely received a comparable amount of weekly individual and/or group in-house supervision (60-90 minutes per person).

Participants: Therapists

The 2 protocols were delivered in existing services by 49 agency clinicians. Randomization occurred at the therapist level: Volunteer therapists at each site were randomly assigned to a study condition. Thus, “therapist” was the clustering variable in the design, and study clients were nested within study therapists. To maximize delivery of the MIP across study cases, we weighted randomization to favor 2:1 proportional assignment to the integrated condition. Note that it was not possible to randomize also at the client level (ie, doubly randomized design24) because partner clinics were not able to assign clients randomly to study therapists without disrupting routine client flow and therapist caseload management. All full-time clinicians and clinical trainees at each of the 5 partner sites were invited to participate in the study on a volunteer basis. All therapists at each site were consented, provided data on clinical training background and site organizational characteristics, and then convened for a 90-minute on-site introductory training in the CASH-AA protocol. At the end of the training, therapists were randomly assigned to either the behavioral-only condition (CASH-AA only) or the integrated condition (CASH-AA plus MIP). Those randomly assigned to the integrated condition were then invited to participate in an additional 90-minute on-site introductory training in the MIP. These same training and randomization procedures were followed whenever new therapists were hired at each site. In a few instances, when the number of active therapists in a study condition at a given site dipped to <3 due to staff turnover, the next therapist to volunteer at that site was assigned directly to the low-member condition to maintain critical mass for group-based protocol consultation meetings. Of the total 49 therapists enrolled in the study across all sites and assigned a case, <10% were assigned group membership in this fashion, rather than being randomized; this proportion did not significantly differ among study sites. As shown in the CONSORT diagram (Figure 1), 82 therapists consented to participate and were assigned to a study condition (50 integrated, 32 behavioral only); of these, 49 (60%) eventually received a study case and therefore became study therapists (29 integrated, 20 behavioral only).

Figure 1. CONSORT Participant Referral and Flow Diagram.

Figure 1

CONSORT Participant Referral and Flow Diagram.

Participants: Clients

All study clients were recruited from existing clinical referral streams at the 5 partner sites. Recruitment followed a 2-gate strategy: (1) Intake staff at each site pitched the study to all families during the clinic's routine intake process; and (2) study therapists at partner sites pitched the study to families of those adolescents on their existing caseloads who had not already been recruited for the study. At both gates, the clinic staff member attempted to obtain permission to share family contact information with research staff. When permission was granted, clinicians contacted research staff by phone to relay contact information.

Research staff attempted to contact the primary caregiver of referred families by phone within 24 hours of referral receipt. During the initial call, research staff described the main features of study participation; collected data on adolescent age, race/ethnicity, and sex; and obtained verbal consent to administer a brief ADHD screening tool.25 Families who screened positive (ie, caregiver score on the screening tool adding to at least 10 on inattention/disorganization and/or hyperactivity/impulsivity scales rating each of 10 symptoms on a Likert-type scale from 0 to 3 for the adolescent) were immediately recruited to schedule an in-person home-based baseline assessment to determine full study eligibility; those who refused to schedule a baseline interview were asked about their primary reason(s) for refusing. During the baseline assessment, caregivers and adolescents were consented and interviewed separately; caregivers consented for themselves and their teenagers, and teenagers assented for themselves. Caregiver assessments were administered in the preferred language: 81% English and 19% Spanish. Assessment measures consisted of a structured clinical interview and audio computer-assisted self-report measures of adolescent clinical symptoms, school performance, other aspects of developmental functioning, family characteristics, history of treatment engagement and medication use, and legal system involvement. Each family member received an honorarium in gift cards for completing the baseline assessment, which typically lasted 60 to 90 minutes.

Study inclusion criteria were (1) adolescent was aged 12 to 18 years; (2) primary caregiver was able to participate in treatment; (3) adolescent met DSM-5 diagnostic criteria for ADHD, based on either caregiver or adolescent report; (4) adolescent was not enrolled in any behavioral counseling at any other site; (5) caregiver expressed desire, and adolescent expressed willingness, to participate in treatment at the partner site; and (6) family had health insurance benefits that were accepted for routine behavioral services by the given partner sites (all sites accepted a broad range of insurance plans, including Medicaid). Exclusion criteria were mental retardation or autism spectrum disorder; psychiatric or other medical illness requiring hospitalization; current psychotic symptoms; active suicidal ideation; or severe SU problems that require immediate relief (detox or residential placement). No inclusion or exclusion criteria were related to medication status; that is, youth were permitted to be either taking or not taking medications of any kind at study enrollment, and to change their status at any time during the study.

Interventions and Comparators

Therapists in the behavioral-only condition were trained in the use of CASH-AA; therapists in the integrated condition were trained in the use of CASH-AA and MIP. Full descriptions of the protocols are contained in Appendix A. Note that the study placed no conditions or restrictions on the natural tenure of each case in treatment (ie, each study case remained enrolled in treatment at the full discretion of the partnering clinics, and protocols were implemented at full discretion of the study therapists). No matter the length in treatment for any given case, for every case (1) research staff conducted home-based assessment interviews at 3, 6, and 12 months after the baseline assessment interview; and (2) study therapists were asked to submit protocol fidelity data (post-session self-report checklists, session audio recordings) for all sessions convened throughout the course of the 1-year research follow-up period.

Changing Academic Support in the Home for Adolescents With ADHD

CASH-AA21 is a 3-module protocol that uses family and individual sessions to improve school performance. Module 1: Motivation and Preparation engages adolescents as active participants in improving school performance, assesses home environment characteristics that support or impede school success, and determines caregiver and adolescent readiness to make changes in the home academic setting. Module 2: Behavior Change implements family-centered interventions designed to boost school attendance (as needed), collaboratively develops a homework management plan to incrementally increase the amount of distraction-free time spent nightly on school assignments, and helps the teen create an efficient system for organizing school assignments and materials. Module 3: Therapist-Family-School Partnership provides family education and advocacy training on special education rights and school-based services and assists families in solidifying partnerships with in-school advocates to monitor education plans and academic progress. Note that CASH-AA is a clinically flexible protocol that does not prescribe a fixed number of sessions or specific sequence of interventions. That is, study therapists were trained and supervised to make case-by-case decisions, based on individual clinical presentation, about when to implement any aspect of the protocol, for how long in a given session, and in what sequences within and between sessions.

Medication Integration Protocol

MIP is a family-based protocol designed to integrate medication services into behavioral treatment planning for adolescents with ADHD.22 It contains 5 modular tasks. In ADHD Assessment & Medication Consult, therapists consult with prescribers to confirm ADHD diagnosis and medication eligibility; they also help families understand the results of psychiatric evaluation. In ADHD Psychoeducation & Client Acceptance, therapists and families review ADHD psychoeducational materials to prompt interactive discussions about key ADHD issues, promote basic acceptance of the condition and practical expectations for change, and complete checklists of ADHD-related characteristics and common impairments in 3 domains (family, school, and peer) to generate each teen's unique “ADHD profile.” In ADHD Symptoms & Family Relations, therapists engage teens as active participants in remaining therapeutic activities, address negative attributions about ADHD-related behavior by highlighting mislabeled causes (“relabeling”), redefine adolescent referral problems as family problems with potential family solutions (“reframing”), assess home environment characteristics that might support or impede treatment success, and gauge family readiness to make therapeutic changes. In ADHD Medication & Family Decision-Making, therapists educate families about potential benefits and adverse effects of ADHD medications in various contexts (home, school, peer), detail the trial-and-error approach to medication dosing, raise issues regarding stigma and medication misuse, and collaborate with families to process key factors that inform decisions about medication fit. In Medication Management & Integration Planning, for families that initiate medication, therapists play a lead role in case coordination for medication management that is tailored to each family, with therapists and prescribers working in an integrated fashion to support prescription compliance and monitor benefits and adverse effects. Note that, as described previously for CASH-AA, MIP is a clinically flexible protocol that does not prescribe a fixed number of sessions or specific sequence of interventions. Pilot study results23 support the feasibility of MIP and its positive impact on ADHD medication use (medication evaluation, acceptance, and duration) in routine outpatient behavioral care.

Throughout the study, 2 monthly protocol consultation meetings were convened at each partner site. Consultation meetings were moderated by 1 of the developers of the 2 treatment protocols (Dr Hogue or Molly Bobek, LSCW). To guard against crossover effects, 1 meeting was attended by therapists in the behavioral-only condition and a separate meeting was attended by therapists in the integrated condition. The goal of these meetings was to support therapists in integrating treatment protocols into routine treatment planning for study cases, including consultation on the timing, sequencing, and dosage of various protocol components.

The primary threat to the internal validity of this design was MIP crossover effects: Behavioral-only therapists at any given site might have adopted MIP-consistent interventions after having been exposed to MIP principles during day-to-day interactions with their colleagues in the integrated condition; similarly, site psychiatrists may have started to use MIP-consistent practices when collaborating with behavioral-only therapists. The occurrence of crossover effects (ie, experimental contamination) was deterred via on-site training, expert consultation on protocol implementation, and protocol fidelity monitoring procedures, as described in the next section.

Fidelity Evaluation

We used a 2-pronged approach to evaluate therapists' fidelity to CASH-AA and MIP: (1) therapist reports of the extent to which each of their sessions with study participants focused on ADHD, ADHD medication, and elements of CASH-AA and MIP; and (2) observational coding of audio recordings of therapy sessions conducted by research staff who were blind to study condition and had participated in extensive and ongoing training in observation techniques and tools by the PI and project director. Study therapists were asked to record as many sessions as possible. It was deemed important to collect therapist self-report fidelity data in addition to session audiotapes for 2 reasons: (1) We believed we would collect a substantially greater number of self-report checklists covering a much larger proportion of convened sessions, thereby providing a more extensive scope on treatment fidelity; and (2) we anticipated that observational data might confirm that some self-report fidelity data points were reliable, enabling interpretation of those data for the much larger proportion of sessions for which there was therapist-report fidelity.

Audio recordings were collected for more than half of the sessions for which therapists submitted session data (54.7% [n = 571]). Study therapists were encouraged to record as many sessions as possible for all families who consented to allow session recordings; therapists were informed which families declined to allow recordings at the consent process, which amounted to 14% of all participants. Of the 49 therapists enrolled in the study (n = 20 in behavioral only; n = 29 in integrated), 14 (29% of all therapists: 4 [17%] behavioral only, 10 [35%] integrated) submitted at least 1 audio-recorded session. It is not known to what degree the recorded sessions are representative of all convened sessions. The main reasons voiced by study therapists for not recording treatment sessions were therapist belief that recording sessions would negatively impact treatment; therapist discomfort at being recorded; therapist belief that session recording and data submission were overly burdensome; therapist report that participants declined to allow recording during sessions; and therapist failure to access recording equipment before the session.

Of those sessions that were recorded, a random selection (68.0% [n = 388 sessions]) was observed and coded by at least 1 trained research team member. Of these, 242 were double-coded for CASH-AA use, and 58 were double-coded for ADHD, ADHD medication, and MIP use. Interclass correlation coefficients (ICCs) were computed to determine the interrater reliability of coder pairs that was documented for these double-coded tapes. Results indicated that coders were fairly to highly reliable in their coding of the number of minutes in session spent focused on ADHD, ADHD medication, CASH-AA protocol use, and MIP use (ICCs, 0.69-0.86). Therefore, the remainder of coded tapes were single-coded.

According to therapist report, of the total number of sessions for which data on protocol delivery were submitted (N = 1051), 354 sessions (34% of the total) contained some delivery of the CASH-AA protocol, and 109 sessions (10% of the total) contained some delivery of the MIP. According to observational coder report, of the total number of sessions for which a submitted audio recording was coded (n = 501 and 387 for CASH-AA and MIP, respectively), 336 sessions (67% of the total coded) contained some delivery of the CASH-AA protocol, and 117 sessions (30% of the total coded) contained some delivery of the MIP.

Interrater reliability coefficients were again computed, this time examining the reliability between observational fidelity evaluations (the mean of the 2 coder ratings was used for those that were double-coded) and therapist-reported fidelity evaluations, to determine the accuracy of therapist self-reports of their time in session focused on ADHD, ADHD medication, CASH-AA use, and MIP use. Interrater reliability was low for ADHD and CASH-AA and MIP use (ICCs, 0.10-0.26) but was acceptable for session time focused on ADHD medication (ICC, 0.53). Therapist-reported and observational mean fidelity scores are shown in Table 1. Independent sample t tests were conducted to compare conditions on fidelity scores. Because these were preliminary descriptive analyses, therapist clustering was not accounted for.

Table 1. Session Time Focused on ADHD, ADHD Medication, and Study Protocol Use in Minutes.

Table 1

Session Time Focused on ADHD, ADHD Medication, and Study Protocol Use in Minutes.

Therapist reports of fidelity indicated that those in the integrated condition spent significantly more time focused on ADHD generally than those in the behavioral-only condition (t = 3.15; P < .01); however, this was not supported by coder reports of fidelity (t = 0.37; P = .72). Therapist reports of time spent in session focused on ADHD medication identified a trend-level difference, with therapists in the integrated condition reporting more time spent discussing ADHD medication than therapists in the behavioral-only condition (t = 1.69; P = .09). Therapists across both conditions reported no significant difference in amounts of time spent on elements of the CASH-AA protocol in session (t = 0.49; P = .63), which was supported by coder reports (t = 0.21; P = .84). In contrast, therapists in the integrated condition reported spending significantly more session time focused on elements of the MIP (t = 2.53; P < .05). This was not supported by coder observations, however, in which coders identified no significant difference in use of elements of the MIP between the 2 conditions (t = 1.16; P = .25).

Several primary themes emerged from these analyses. First, therapist self-reports of protocol adherence indicated strong treatment fidelity overall: (1) There were no differences between conditions in delivery of CASH-AA protocol elements, which was common to both study groups; (2) integrated therapists delivered a greater amount of MIP elements; (3) integrated therapists devoted more session time to discussing ADHD issues (significant effect) and ADHD medication (trend-level effect). Second, coder ratings based on the content of the audio-recorded sessions were congruent with therapist ratings only for amount of time spent discussing ADHD medication; they were discrepant for all other fidelity ratings. Third, coder ratings indicated overall fidelity with regard to CASH-AA delivery (ie, they reported no significant difference between conditions) but not with regard to MIP fidelity (ie, they reported no significant differences among conditions on MIP delivery, discussion of ADHD issues, or discussion of ADHD medication).

Study Outcomes: Primary (Aim 1) Adolescent Functioning

ADHD symptoms were assessed using the Mini International Neuropsychiatric Interview (MINI), v.5.0.26 The MINI is a brief structured diagnostic interview that assesses DSM-IV diagnoses in adolescent and adult populations. The MINI is specifically designed to be administered by lay interviewers and has demonstrated solid interrater and test-retest reliability in 2 international samples of psychiatric and nonpsychiatric patients,27 as well as excellent convergent validity with both the Structured Clinical Interview for DSM Disorders (SCID) and the Composite International Diagnostic Interview (CIDI).26-28 Two adolescent-reported and 2 caregiver-reported dimensional variables were calculated: total number of symptoms endorsed (of 9) on the Inattentive/Disorganized subscale and total (of 9) on the Hyperactive/Impulsive subscale.

Externalizing and internalizing symptoms were measured with the Child Behavior Checklist (caregiver report)29 and Youth Self-Report30 (adolescent report), which are parallel measures of youth behavior problems supported by extensive evidence encompassing reliability, validity, and clinical utility31 and used with a wide range of adolescent samples.32-34 Each contains a summary scale of externalizing symptoms (rule-breaking, oppositional, and aggressive behaviors; 32 and 35 items, respectively) and internalizing symptoms (anxious/depressed, withdrawn, and somatic complaint behaviors; 31 and 32 items, respectively). Higher scores correspond to more symptoms; scores on each item range from 0 to 2, and the study variable was calculated by summing items within each scale.

Delinquency was assessed using the National Youth Survey Self-Report Delinquency Scale (SRD),35 a self-report delinquency scale used in the National Youth Survey36 to assess adolescent criminal behavior and peer criminal behavior according to 5 subscales: Total Delinquency, General Theft, Crimes Against Persons, Index Offenses, and Drug Sales. The SRD is a well-validated instrument37 used extensively with African American and Hispanic populations38 and with adolescent clinical samples.1,22 Adolescents reported on the number of times they engaged in various overt and covert delinquent acts.

SU was captured with the Comprehensive Addiction Severity Index for Adolescents (CASI-A),39,40 a semistructured clinical interview that yields information about SU during the past 30 days as well as the severity of SU risk factors and consequences. The CASI-A has demonstrated strong reliability and validity with clinical record reviews of adolescents receiving inpatient psychiatric or substance abuse treatment39 and with other diagnostic interviews such as the CIDI and DiSC (behavior assessment based on 4 personality traits: dominance, influence, steadiness, and conscientiousness).40 Teens reported on the number of days they used any alcohol or illegal drugs in each month of follow-up. An adolescent was categorized as “SU+” if they (1) met DSM-5 criteria for SU disorder at baseline or (2) were enrolled in treatment at the SU treatment site; otherwise, they were categorized as “SU−”. Of the 145 participants in the analyzed group (Figure 1), 46 (32%) were SU+ and the remainder SU−.

Executive functioning was measured with the Behavior Rating Inventory of Executive Function (BRIEF), a caregiver-report measure of behavioral problems that are linked to executive functioning and commonly observed in youth with ADHD.41,42 Gioia et al41 reported good convergent and discriminant validity between the BRIEF and similar behavioral rating systems as well as test-retest reliability statistics ranging from 0.79 to 0.88 during a 2-week period; internal consistency ranging from α = .80 to .98; and interrater reliability between parent and teacher responses of r = 0.32. The BRIEF has been validated in ADHD outpatient samples43 and teens with mixed clinical diagnoses.44 This study used 2 scales, the Behavioral Regulation Index global scale (Inhibition, Behavioral Shift, and Emotional Control subscales) and the Plan/Organize scale. Higher scores correspond to greater difficulty with behavior regulation and organization; scores on each item range from 0 to 2, and the study variable was calculated by summing the scores on each scale.

School functioning was measured with 4 variables. School grades and minutes spent doing homework were measured using the CASI-A39 (described earlier), a semistructured adolescent clinical interview with strong reliability and validity39,40 and concurrent validity for treatment-seeking adolescents.25 This measure captured school grades (responses mapped grade numerals onto a continuous scale ranging from 0 to 7), with higher scores indicating better grades. Adolescents also reported on the number of minutes spent doing homework each day. Academic self-efficacy was measured using 4 items from the Self-Efficacy for Learning and Performance subscale of the Motivated Strategies for Learning Questionnaire.45 Adolescents indicated to what extent they felt certain they could understand the most difficult material presented in texts and could master the skills being taught, and felt confident they could understand the most complex material presented by their teachers and could do an excellent job on assignments and tests. Higher scores indicated higher academic self-efficacy; scores on each item range from 0 to 3, and the study variable was calculated by averaging the z-score of the 4 items. Homework management was measured with the inattention/avoidance items of the Homework Problems Checklist.46,47 This caregiver-reported measure consists of 11 items that probe a number of homework problem behaviors (eg, complaining about homework, waiting until the last minute, producing messy homework) over the past 2 weeks. Higher scores indicate more problems with homework; scores on each item range from 0 to 3, and the study variable was calculated by summing the scale items.

Study Outcomes: Secondary (Aim 2) Service Use

Treatment attendance (total number of individual, family, and group sessions attended) and medication management sessions were collected from agency records. Medication use, coded as “on” or “off” medication at each follow-up point, was captured with the Services Assessment for Children and Adolescents,48 a parent-report structured interview that assesses attendance in outpatient services and use of psychiatric medications and has strong validity, test-retest reliability, and reliability between parent and child reports.48,49 Note that the study ultimately did not collect data on treatment satisfaction. Just before enrolling initial study cases, we completed review of treatment satisfaction data from a randomized trial conducted with a highly similar client population in the same geographic area.50 Those data clearly indicated that virtually every study participant (adolescents and caregivers) reported satisfaction at or near the top score of the given measure, effectively eliminating meaningful variance due to a pronounced ceiling effect. For this reason, and to reduce interview burden on clients in the current study, we elected not to collect treatment satisfaction data in this trial.

Sample Size Calculations and Power

Sample size for all 3 study aims was N = 145. Power analyses for main effects and interactions under nested designs were conducted using established formulas51,52 and replicated in 2 software packages.53,54 While accounting for the ICC, which typically reduces the effective sample size compared with the size realized under the assumption of independence between clients in a cluster, we noted a range of power to detect the specified interaction effect (of approximately 4% of explained variance). We assumed holding type I error to 5%, that 140 cases would be nested within 15 to 20 study therapists, and that the ICC of case outcomes within therapist would fall within the typical range of 0.005 to 0.03,55,56 although recent experiences suggest ICCs toward the upper range. Following established formulas for nested designs,57,58 Table 2 illustrates study power to detect effects of R2 given our assumptions. At a conservatively estimated magnitude of an ICC of 0.03, we calculated that we would be able to detect medium to large main effects when testing for client outcomes (inattention and hyperactivity symptoms), and at least moderate power to test for interactions between study condition and baseline SU (SU+ vs SU−) whenever there were less-than-large effects.

Table 2. Study Power to Detect Effects.

Table 2

Study Power to Detect Effects.

Time Frame for the Study

The study began in April 2015 and concluded in August 2018. Between April and June 2015, project staff were hired and trained, and materials were finalized. Between June and August 2015, clinicians, supervisors, and administrative staff at the study sites were introduced to the study, consented to participation, and participated in trainings on the 2 study protocols. In August 2015, 2 families participated in pilot screening and baseline interviews to assist the research team in finalizing the data collection processes and materials. The first participating families were recruited, screened, and enrolled in September 2015, and enrollment continued until February 2018. Data collection was completed with families and study sites on August 31, 2018.

Data Collection and Sources

Data were collected from families participating in the study and from clinicians and clinical site records. At the completion of the baseline interview (described earlier), study-eligible families were immediately offered participation in follow-up home-based interviews at 3, 6, and 12 months after baseline; families who accepted were then immediately consented and scheduled for follow-up interviews. Client participants and research staff assessing client outcomes were blind to treatment condition. All initial screens for eligibility were conducted by telephone with the primary caregiver. All family baseline interviews and most follow-up interviews were conducted in the family home with both the caregiver and adolescent present with the research staff member who was conducting the interviews. On occasion, families with scheduling conflicts were offered the opportunity to participate in telephone-based follow-up interviews; 11 families chose this option for at least 1 follow-up interview. In 6 cases, adolescents were transferred to residential treatment or detained by the juvenile justice system, which meant they were unable to participate in follow-up interviews in person. In these cases, caregivers were interviewed in the family home, and for adolescents in residential treatment, efforts were made with the treatment site supervisor to schedule supervised phone-based interviews. Retention rates for each of the follow-up interviews were high (94%-96%), and only 2 families neglected to participate in all follow-up interviews.

Session data were collected from therapists via audio recording and from questionnaires completed after each session with study families. Research staff members traveled to each study site once every 2 weeks to collect audio recordings and questionnaires. Between July and August 2018, research staff worked with site administrative staff to collect data pertaining to the number of sessions attended by each study family. Length of client participation in treatment services varied based on routine clinical decision-making by the partner agency.

Analytical and Statistical Approaches

All data were housed at Center on Addiction, and all analyses were conducted by Center on Addiction research staff on computers belonging to the center. Staff at partnering sites did not have access to raw study data.

Preliminary Analyses and Refuser Analyses

All analyses were preceded by examining distributional properties of variables and outliers to assess the need for using transformed variables or nonparametric tests. We examined whether randomization successfully created equivalent study groups by conducting t tests or chi-square tests on demographics and other variables; no significant differences were found.

Analytic Strategy to Account for Nesting Effects

This study used a nested design: clients were nested within therapists, and therapists were nested within treatment sites. In a nested design, the application of a standard fixed-effects general linear modeling typically produces biased inferential tests because the error terms of units within each nested level are often correlated.59 We used the sandwich estimator to adjust parameter estimates and standard errors to account for client nesting within therapists.60 This approach is used to analyze nested data when the goal is to examine outcome effects at the level of the individual (ie, client), and the hierarchical structure of the data (ie, client nesting at therapist level) is akin to a nuisance factor to be accounted for, but inference about the degree of correlation is not of interest. Also, the design was nested at the level of treatment site: Therapists were nested within the site. Recommendations stipulate that 10 to 20 independent units at any given cluster level are needed to produce stable estimates for random-effects modeling.61 Because this study included only 5 sites, we adopted the typical alternative of modeling site as a fixed effect included as a nuisance covariate in analyses. Because site was never a statistically significant covariate in any analyses, the final reported results do not include it. This approach is the norm for multisite studies in behavioral sciences62 with a small number of participating sites.

Our base analytic approach in conducting all study analyses was a multiple-indicator multiple-cause latent growth curve (LGC) variable modeling approach as detailed in Newsom63 and implemented in the statistical software Mplus, v.8 (https://www.statmodel.com/). In this approach, latent growth parameters (eg, intercept, linear, quadratic, etc) are regressed on a dichotomous time-invariant covariate representing treatment condition and coded 0 (representing the behavioral-only group: CASH-AA only) and 1 (representing the integrated group: CASH-AA plus MIP). Several examples in the treatment literature have followed these methods, including our own previous studies.33 Note that when the LGC approach we used is recast (ie, translated) as a mixed-effects analysis of variance or multilevel modeling approach, this introduces commonly trafficked terms and ideas such as “interaction between time effects and condition” that we use in this report to facilitate interpretability (as detailed in Singer and Willett64).

Plan of Analysis for Main Outcomes: Aims 1 and 3

LGC65 was used to examine the impact of treatment condition (CASH-AA plus MIP vs CASH-AA only) on change over time in client outcomes: symptoms (ADHD, internalizing and externalizing, delinquency, SU) and QOL indicators (executive and school functioning). LGC produces estimates for the growth curves (ie, trajectories) of each individual and then aggregates individual curves to estimate mean growth parameters (intercept and slope) across participants, characterizing the sample in terms of the average baseline value of the dependent measure (intercept) and the rate and shape of change in the dependent measure over time (linear and quadratic effects). Each growth model yields a parameter estimate (B, akin to a regression coefficient) for the effect of each independent variable on the intercept and slope parameters. Parameter estimates are tested for significance using the pseudo-z test, which is calculated by dividing the B coefficient by its standard error. For all analyses, the behavioral-only condition is coded as 0 and the integrated condition is coded as 1. Analyses used a 2 (treatment condition) × 4 (time) repeated measures intention-to-treat (ITT) design; missing data (ie, outcome data lost to follow-up) were handled with robust maximum likelihood estimation (MLE; described under “Analytic Plans for Missing Data”). For linear effects, time (captured by 4 follow-up assessment points) was coded as 0, 1, 2, 3 (per convention, to represent straight lines). For quadratic effects, time was coded as 0, 1, 4, 9 (per convention, to represent exponential curves).

LGC proceeded using Mplus v.8.2.66 First, we tested a series of growth curve models for each outcome, using chi-square difference tests of nested models to determine the overall shape of the individual change trajectories (linear change or quadratic change); overall model fit was evaluated by examining the chi-square, root mean square of approximation, comparative fit index, and Tucker-Lewis index. For those outcomes demonstrating quadratic change, parameter estimates for both linear and quadratic effects are presented. For those outcomes demonstrating linear change, only parameter estimates for linear effects are presented. Second, we tested unconditional models for outcomes of all participants to obtain the average effect for change over time in outcome, without including treatment condition or other covariates. Although this analysis does not test a specific hypothesis, the unconditional models provide the clearest test of time effects (ie, whether the sample improved as a whole, regardless of condition), and it is traditionally reported in randomized controlled trials using this approach. Third, we added condition (behavioral only vs integrated) to the models to test its impact on initial status and change over time, providing the analyses for hypotheses 1 and 2. These models controlled for the following confounding variables (which also serve as moderators in moderator analyses): sex (male vs female); age (<15 years vs ≥15 years); race (non-Hispanic White vs all others [ie, any other race]); and baseline SU (SU+ vs SU−). Each variable was operationalized as a dichotomous variable for moderator analyses because dichotomization facilitates (1) interpretation of interaction effects involving moderator variables, and (2) post hoc analyses aimed at diagnosing significant interaction effects. We selected 15 years as the cut point for the age moderator variable because it was the cut point that created greatest equivalency in participant numbers between groups. These analyses provided the results for aim 1. Treatment effects (aim 1) for any given outcome were shown by a statistically significant slope parameter, as tested by the pseudo-z test—calculated by dividing the coefficient by its standard error—associated with condition (ie, study group).

Heterogeneity of treatment effects (HTE; aim 3) for each outcome was tested via the following steps. First, we tested a model including condition, the potential moderator (sex, age, race, or baseline SU), and a term to test their interaction. Note that condition and potential moderators were grand mean centered before computing interaction terms. If the interaction was significant, post hoc analyses examined condition effects within subgroups defined by the potential moderator (eg, male vs female). If the interaction was not significant, the interaction term was removed from the model to test for main effects of the potential moderator on each outcome. As described previously, we used the sandwich estimator to control for therapist nesting.

For all analyses in aims 1 and 3, we relied on the results of the unconditional models to determine whether to include a quadratic effect. For models that included quadratic effects, if these effects were statistically significant based on P values, we report the parameter estimates for linear and intercept effects in the tables but do not interpret them, because interpretation of significant linear effects in the presence of significant quadratic effects is misleading. In these instances, the linear coefficients reported in the tables were obtained in the presence of quadratic terms. If the quadratic effect was not statistically significant, we ran the model again without the quadratic effect to test the linear effect. In these cases (indicated by table notes), the linear effects reported in the table were obtained in models that did not include quadratic terms.

We did not test intercept-only models, because these effects were not relevant to study aims; baseline condition differences were examined in a separate analysis. For normally distributed outcomes, we used standard LGC models. For the 1 outcome that deviated substantially from normality (delinquency), we used 2-part growth curve models,67 which allow for the simultaneous estimation of separate but correlated continuous and categorical LGC models. Two-part models were selected because the non-normal outcome data were caused by a substantial number of participants reporting absence of the outcome variable (ie, no delinquent activities). In 2-part models, the original distribution of the outcome is separated into categorical and continuous parts, each modeled by separate but correlated growth functions. In the categorical part, a binary indicator variable is created to indicate any vs none of the outcome in question. The continuous part models the frequency of occurrence of the outcome given any positive occurrence. We previously used 2-part models to test delinquency and ASU outcomes in a highly similar sample.68

Finally, for research question 2 pertaining to individual differences, we followed the same template as described for HTE analyses, testing medication status at follow-up as a potential moderator of condition effects on outcomes, followed by examination of main effects of medication status for those outcomes for which the interaction was not significant. The medication status variable was coded as 1 for clients who were not taking medication at baseline and subsequently started medication at any point during the follow-up period; it was coded as 0 for everyone else. By coding in this fashion, we were able to examine correlates of a pure “medication initiation” effect, given that medication initiation is a primary (but not the only) function of the MIP featured in the integrated condition.

Plan of Analysis for Main Outcomes: Aim 2

Linear regression in Mplus v.8.2 was used to examine condition effects on treatment and medication management session attendance, controlling for nuisance covariates. As discussed earlier, to control for therapist nesting effects, we used the sandwich estimator.69 Missing data were handled with robust MLE (discussed further below). We examined condition effects on medication initiation in 2 ways. First, we used LGC, following the same steps as those described previously for aims 1 and 3 to examine whether clients in the integrated condition were more likely to be taking ADHD medication across the follow-up period. Second, we conducted a simple chi-square test to determine whether clients in the integrated condition were more likely to start medication at some point during the follow-up period.

Analytic Plans for Missing Data

Based on 20 years of experience engaging high-risk adolescents and their families in longitudinal research, we expected to have rates of missing assessment data on outcome variables between 10% and 15%. All proposed analyses involving client outcome data were carried out in Mplus, which provides full information MLE; MLE produces unbiased parameter estimates under the assumption that data are missing at random (MAR).69-71 Moreover, MLE outperforms other missing data approaches, such as listwise deletion, even when MAR is not met.72 Because attrition at follow-up was negligible at each time point and across the entire sample (see Figure 1), we did not conduct sensitivity analyses to address issues of incomplete follow-up.

Changes to the Original Study Protocol

Two changes were made to the original study protocol; both were approved by PCORI and the IRB office at Center on Addiction. First, an amendment was made to add a fifth partnering treatment site about halfway through the study. The addition of this fifth site, one that focused on treating ASU problems, ensured that we would reach our goal of a final sample consisting of a large subpopulation of adolescents with ADHD and co-occurring SU. In addition, this fifth treatment site allowed us to add 12 additional therapists to our sample.

Second, an amendment was made to incorporate a qualitative data component into the study protocol in the form of focus groups with participating clinicians and supervisors at partnering treatment sites. Focus group questions asked participants to reflect on the study protocols and materials provided, in particular, whether and how therapists found the CASH-AA and MIP interventions useful, which specific elements and modules fit most seamlessly into the treatment they typically offer, which adolescents seem to benefit the most from these protocols, how successful the protocols had been for adolescents, and how they might suggest adapting the protocols to better suit the population and treatment setting. Focus groups were conducted at each of the 5 partnering treatment sites during the final year of the study and yielded rich information to improve the substance and design of the protocols in ways that were meaningful to study stakeholders. The procedures and findings of qualitative data analyses are described in Appendix B.

Results

The CONSORT diagram (Figure 1) shows that of the 257 families who participated in the initial phone screen, 58 (22.6%) were determined to be ineligible. In 45 of these families, adolescents did not meet screening eligibility criteria for ADHD, 6 dropped out of treatment at the partnering site before a screening was completed, 2 were transferred to inpatient treatment before or soon after screening, 2 moved out of state and were therefore no longer attending a partnering clinic, 1 was assigned a nonstudy therapist, and 2 were determined by research staff to be ineligible due to other psychosocial issues (ie, endorsing psychotic symptoms; developmental delay). In addition, 23 families (8.9%) refused to participate in the baseline assessment after being determined eligible for the study during the screening. Reasons for refusal included caregivers feeling overwhelmed with accessing treatment and not wanting to add further commitments; caregivers and/or adolescents not having time to participate in interviews; caregivers not wanting ADHD to be a focus of treatment; and miscellaneous other reasons.

Of the 176 families who participated in baseline interviews, 31 (17.6%) did not meet eligibility criteria. Twenty-two adolescents did not meet ADHD diagnostic criteria, 3 exhibited serious suicidal risk, 2 were assigned to nonstudy therapists, 2 had dropped out of treatment by the time they participated in the baseline interview, 1 was diagnosed with a developmental disorder, and 1 was excluded from the study due to another family crisis. This left us with a final sample of 145 families. Follow-up interview rates were excellent across time points: 94% at 3 months, 95% at 6 months, and 96% at 12 months. Of the 145 total families enrolled in the study, 143 (98.6%) completed at least 1 follow-up interview. Follow-up completion rates did not differ between conditions at any time point.

Sample Characteristics

Demographics and other clinical characteristics of the client sample (N = 145), as well as baseline values of all client outcome variables, are presented in Table 3a for the whole sample and separately by condition. As shown in Table 3a, the adolescents enrolled in the study were 72% male and 42% White non-Hispanic, 37% Hispanic American, 15% African American, and 6% more than 1 race; the average age was 14.8 years. There were no significant differences between study conditions in any of the demographic and clinical characteristics listed in Table 3a, indicating that randomization at the therapist level resulted in equivalent distribution between treatment conditions on all measured characteristics.

Table 3a. Baseline Demographic and Clinical Characteristics for the Full Sample and Separately by Condition.

Table 3a

Baseline Demographic and Clinical Characteristics for the Full Sample and Separately by Condition.

Therapist participants (N = 49) were 82% female and 63% White non-Hispanic, 29% Hispanic American, and 10% some other race/ethnicity; their average amount of postgraduate experience was 5.1 years. A total of 72% had a terminal master's-level degree, 10% had a bachelor's-level degree, 8% were at the PhD level, 6% were at the MD level, and 4% were unknown. There were no condition differences in therapist characteristics (Table 3b).

Table 3b. Therapist Characteristics by Condition.

Table 3b

Therapist Characteristics by Condition.

Descriptive Statistics on Outcome Variables

The CONSORT diagram (Figure 1) depicts the flow of clients into the study and the interview completion rates. Of the 305 families referred to the study, 48 (15.7%) were determined to be ineligible by research staff before participating in the initial phone screen: 32 families refused to participate in the phone screen, 8 were unable to be reached by phone, 3 had dropped out of treatment by the time they were reached by phone, 2 had children who were too young to be eligible, 2 were dropped due to the family dealing with other family crises, and 1 had been referred to inpatient treatment by the time they were reached by phone.

Descriptive statistics for all outcome variables at each time point are presented in Table 4 separately for the behavioral-only and integrated conditions. The distribution for delinquency showed significant departure from normality, hence the use of 2-part LGC models (described previously).

Table 4. Descriptive Statistics for All Outcome Variables by Treatment Condition.

Table 4

Descriptive Statistics for All Outcome Variables by Treatment Condition.

Testing Shape of Change Across Conditions

Chi-square difference tests of nested models were used to determine whether linear or quadratic change best characterized each outcome. Quadratic models produced the best fit to the data for the following outcome variables: adolescent-reported inattentive/disorganized symptoms (henceforth “inattentive symptoms” or “inattention”) and hyperactive/impulsive symptoms (henceforth “hyperactive symptoms” or “hyperactivity”); caregiver-reported hyperactive symptoms; and adolescent-reported internalizing and externalizing symptoms. For all other outcomes, linear models produced the best fit. Both linear and quadratic parameter estimates are presented for quadratic models, and linear parameter estimates only are presented for linear models.

We first tested unconditional models for all outcomes to obtain the unadjusted growth factors (Table 5). Change in the outcome is indicated by a significant linear or quadratic effect parameter. As described earlier in the analysis plan, when the quadratic effect was statistically significant (ie, P < .05), we did not interpret the linear effect. Significant quadratic effects were found for adolescent-reported inattentive and hyperactivity symptoms, as well as caregiver-reported hyperactivity symptoms, indicating an uptick in symptoms following the initial decline. A similar pattern of significant quadratic effects was found for adolescent-reported internalizing and externalizing symptoms, with initial declines followed by some increases in symptoms. Linear declines were found for caregiver-reported inattentive symptoms and caregiver-reported internalizing and externalizing symptoms. There was no change in delinquency or drug use for the overall sample, for which there was lesser prevalence and severity of symptoms than for ADHD. Linear improvements in self-regulation and self-organization were found, as well as in homework problems. There was no overall change in school grades, academic self-efficacy, or minutes spent doing homework.

Table 5. Unconditional Models Testing Change Across Condition for All Outcomes.

Table 5

Unconditional Models Testing Change Across Condition for All Outcomes.

Comparative Impact on Client Functioning (Aim 1)

To test for condition effects on reductions in symptoms (hypothesis 1) and improvements in QOL (ie, developmental functioning; hypothesis 2), we tested condition effects for each outcome, controlling for nuisance covariates (Table 6). A condition effect was found on the quadratic effect for adolescent-reported ADHD inattentive symptoms. As seen in Table 6, the data show no condition impacts on the intercept (baseline value) or linear effect for ADHD inattentive symptoms. The pseudo-z test for condition effects on the quadratic effect parameter is statistically significant, suggesting a group difference in the shape of change over time. Figure 2 shows that behavioral-only clients showed an initially steeper rate of decline in ADHD symptoms, followed by a later increase in symptoms after 6 months, whereas integrated clients showed a steadier rate of decline in ADHD inattentive symptoms over the follow-up period. No other condition effects on ADHD symptoms were found. Regarding comorbid problems, an effect of condition was found for number of delinquent acts. Among clients who engaged in any delinquency, integrated clients showed greater declines in the number of delinquent acts compared with clients in the behavioral-only condition. No other condition effects on comorbid problems or QOL were found. Overall, statistically significant differences favoring the integrated condition were found for 3 of the 18 outcomes analyzed.

Table 6. Condition Effects on Outcomes Controlling for Baseline Covariates (Sex, Age, Race, Baseline SU).

Table 6

Condition Effects on Outcomes Controlling for Baseline Covariates (Sex, Age, Race, Baseline SU).

Figure 2. Condition Effects on Adolescent-Reported ADHD Inattentive Symptoms.

Figure 2

Condition Effects on Adolescent-Reported ADHD Inattentive Symptoms.

Comparative Impact on Service Use (Aim 2)

We conducted linear regression controlling for nuisance covariates to test for condition differences in behavioral therapy attendance (sum of individual, family, and group sessions) and logistic regression controlling for nuisance covariates to test for condition differences in whether clients ever attended a medication management session (hypothesis 3). Due to a low number of medication management sessions (ie, sessions in which family members were seen by a physician to discuss medication) attended (41% of the sample never attended any), this variable was dichotomized for analysis. No condition effects were found for either behavioral therapy or medication management attendance (Table 7). To examine heterogeneity of effects as in aim 3, we also tested for potential moderating effects of sex, age, race, SU identification, and whether the adolescent started ADHD medication during follow-up. There was a moderating effect of baseline SU on behavioral therapy attendance. Probing this interaction revealed a condition effect on behavioral therapy attendance for teens not using substances (B [SE] = 6.36 [2.87]; 95% CI, 0.62-12.10; β = 2.21; P = .027; n = 88), indicating that among teens not using substances, clients in the integrated condition attended more behavioral sessions on average (mean [SD], 19.4 [14.3] sessions) than did behavioral-only clients (mean [SD], 12.8 [11.4] sessions).

Table 7. Condition Effects on Service Use Outcomes Controlling for Baseline Covariates (Sex, Age, Race, and Baseline SU).

Table 7

Condition Effects on Service Use Outcomes Controlling for Baseline Covariates (Sex, Age, Race, and Baseline SU).

To test hypothesis 4, we examined condition differences in ADHD medication uptake. Across conditions, of the 84 adolescents who were not taking ADHD medication at baseline, 24 (29%) initiated medication at some point during the follow-up period. Of the 24 adolescents who initiated medication, 8 were in the behavioral-only condition (33%), and 16 were in the integrated condition (67%). This distribution of adolescents initiating medication did not differ across conditions; that is, 29% in each condition initiated ADHD medication during follow-up. We also examined condition differences in adolescent use of ADHD medication at each time point using the same LGC modeling used for aim 1. No condition effect on ADHD medication use was found (see last rows of Table 6).

HTE (Aim 3)

Results of analyses of HTE by baseline SU (research question 1) are presented in Table 8. No effects were found on executive functioning or ADHD medication use. An interaction between baseline SU and condition was found for caregiver-reported hyperactive symptoms. Regarding comorbid problems, interactions between baseline SU and condition were found for 3 outcomes: adolescent-reported externalizing symptoms, caregiver-reported externalizing symptoms, and delinquent acts. All interactions were probed by testing effects of condition on the outcome variable separately for adolescents identified as not using substances at baseline vs those identified as using substances at baseline. The following condition effects were found for teens not using substances: There was a condition effect on the quadratic effect for adolescent-reported externalizing (B [SE] = 1.15 [0.39]; 95% CI, 0.37-1.93; pseudo-z = 2.91; P = .004) (Figure 3), indicating greater initial declines in symptoms for clients in the integrated condition that leveled off over time. There were no condition effects on caregiver-reported externalizing or delinquency for teens not using substances. The following condition effects were found for teens using substances: There was a condition effect on caregiver-reported hyperactivity symptoms (B [SE] = 0.52 [0.46]; 95% CI, −0.40 to 1.44; pseudo-z = 2.92; P = .004), suggesting that among substance users, behavioral-only clients showed more improvement in hyperactivity symptoms than did integrated clients. There was a condition effect on the linear term for adolescent-reported externalizing (B [SE] = 2.12 [0.66]; 95% CI, 0.80-3.44; pseudo-z = 3.20; P = .001), indicating increases in symptoms for clients in the integrated condition.

Table 8. Models Testing Main Effects of Condition and Baseline SU and Moderating Effect of Baseline SU on Outcomes.

Table 8

Models Testing Main Effects of Condition and Baseline SU and Moderating Effect of Baseline SU on Outcomes.

Figure 3. Condition Effects on Change in Adolescent-Reported Externalizing Symptoms for Clients Who Were Not Using Substances at Baseline.

Figure 3

Condition Effects on Change in Adolescent-Reported Externalizing Symptoms for Clients Who Were Not Using Substances at Baseline.

There was a condition effect on the linear effect for caregiver-reported externalizing (B [SE] = 2.17 [0.84]; 95% CI, 0.49-3.85; pseudo-z = 2.59; P = .010; n = 46), indicating greater declines in symptoms among substance-using clients in the behavioral-only condition. Although there were no condition effects on delinquency in either group, the parameter estimates were in opposite directions, which likely accounted for the interaction effect.

Results of analyses testing HTE by sex (research question 1) are presented in Table 9. Sex × condition interactions were found for multiple outcomes; we report them here to illustrate the overall pattern of results favoring the integrated condition. Interaction effects were detected for adolescent-reported inattentive symptoms and adolescent-reported hyperactivity symptoms. Probing the interactions revealed condition effects for boys only. There were condition effects on the quadratic effect for inattention (B [SE] = −0.45 [0.13]; 95% CI, −0.71 to −0.19; pseudo-z = −3.57; P = .001; n = 104), suggesting an initial decline followed by an increase in symptoms for the behavioral-only condition and a more steady decline in symptoms for the integrated condition. Probing the interaction for hyperactivity symptoms revealed no condition effects in either group. There was an interaction for adolescent-reported internalizing symptoms. Probing the interaction revealed a significant effect on the linear slope for girls (B [SE] = −2.00 (0.94); 95% CI, −3.88 to −0.12; pseudo-z = −2.13; P = .033), indicating greater declines in symptoms among girls in the integrated condition. There were no other effects on comorbid problems or ADHD medication use. Regarding executive functioning, there was a sex × condition interaction on self-regulation. Probing the interaction revealed a condition effect for girls (B [SE] = −1.71 [0.84]; 95% CI, −3.39 to −0.03; pseudo-z = −2.03; P = .042; n = 41), suggesting greater improvement in self-regulation among girls in the integrated condition. There was also a main effect of sex on self-organization, with girls showing greater improvement in self-organization over the follow-up period than boys. Regarding school functioning, a sex × condition interaction was found for minutes spent doing homework. Probing the interaction revealed a condition effect for girls only (B [SE] = 15.58 [5.73]; 95% CI, 4.12-27.04; pseudo-z = 2.72; P = .007; n = 41), indicating greater increases in time spent doing homework among girls in the integrated condition. There was also a main effect of sex on homework problems, with girls showing greater declines in homework problems over the follow-up period.

Table 9. Models Testing Main Effects of Condition and Sex and Moderating Effects of Sex on Outcomes.

Table 9

Models Testing Main Effects of Condition and Sex and Moderating Effects of Sex on Outcomes.

Results of analyses testing HTE by age (research question 1) are presented in Table 10. Main effects of age were found on caregiver-reported inattention and caregiver-reported hyperactivity (Figure 4). Across conditions, older teens showed greater declines in inattention and initial greater declines in hyperactivity, with symptoms increasing at the end of the follow-up period, whereas younger teens' symptoms continued to decline steadily. There was a significant age × condition interaction on the quadratic effect for adolescent-reported internalizing symptoms. Probing the interaction revealed no significant condition effects in either age group; the effects were in opposite directions. No other effects were found on comorbid problems or executive functioning. Regarding school functioning, an age × condition interaction was found for academic self-efficacy. For younger teens, clients in the integrated condition showed greater declines in academic self-efficacy (B [SE] = −0.14 [0.06]; 95% CI, −0.26 to −0.02; pseudo-z = −2.24; P = .025; n = 72), and for older teens, clients in the integrated condition showed greater increases in academic self-efficacy (B [SE] = 0.14 [0.05]; 95% CI, 0.04-0.24; pseudo-z = 2.56; P = .004; n = 73). Finally, there was an age × condition interaction for ADHD medication use. Probing this interaction revealed a condition effect for older teens (B [SE] = 1.19 [0.49]; 95% CI, 0.21-2.17; pseudo-z = 2.43; n = 73). Among older teens, clients in the integrated condition were more likely to use ADHD medication across the follow-up period compared with those in the behavioral-only condition.

Table 10. Models Testing Main Effects of Condition and Age and Moderating Effects of Age on Outcomes.

Table 10

Models Testing Main Effects of Condition and Age and Moderating Effects of Age on Outcomes.

Figure 4. Age Differences in Caregiver-Reported Hyperactivity Symptoms.

Figure 4

Age Differences in Caregiver-Reported Hyperactivity Symptoms.

Results of analyses testing HTE by race (research question 1) are presented in Table 11. As previously described, the moderator variable “race” was operationalized as a dichotomy: non-Hispanic White vs all others (ie, any other race). There were main effects of race on caregiver-reported inattention and self-organization. Non-Hispanic White adolescents showed greater declines in inattention and improvements in self-organization behaviors. Race × condition interactions were found for adolescent-reported externalizing and caregiver-reported externalizing. For adolescent externalizing, condition effects were found for non-White teens only. There was a condition effect on the quadratic effect for adolescent-reported externalizing among non-White teens (B [SE] = 0.84 [0.41]; 95% CI, 0.02-1.66; pseudo-z = 2.07; P = .038; n = 84). Clients in the integrated condition showed greater initial declines in externalizing, but these symptoms began to increase later in the follow-up period. For caregiver-reported externalizing, there was an effect of condition only for non-Hispanic White adolescents (B [SE] = 1.36 [0.53]; 95% CI, 0.30-2.42; pseudo-z = 2.56; P = .011; n = 61), with greater declines in symptoms seen for the behavioral-only condition.

Table 11. Models Testing Main Effects of Condition and Race and Moderating Effects of Race on Outcomes.

Table 11

Models Testing Main Effects of Condition and Race and Moderating Effects of Race on Outcomes.

Analysis of Individual Differences (Research Question 2)

We examined ADHD medication status at follow-up as a potential moderator of condition effects on outcomes. If no moderating effects were found, we tested main effects of medication status on outcomes. In these analyses, we compared the 24 clients who were not taking medication at baseline but started medication at some point during the follow-up period with the 121 other clients. Note that we also ran these analyses limited to the subgroup of 84 who were not taking medication at baseline (24 started medication during follow-up vs 60 who did not), and several of the models did not converge due to the reduced sample size. Therefore, we present the full sample results in Table 12. A medication × condition interaction was found for caregiver-reported hyperactivity. Probing the interaction revealed a condition effect on the quadratic effect for those who started medication (B [SE] = 0.72 [0.25]; 95% CI, 0.22-1.22; pseudo-z = 2.92; P = .003; n = 24). Among those who started medication, integrated clients showed initial decreases in hyperactivity, but symptoms began to increase after 6 months. Behavioral-only clients showed the opposite pattern, with initial increases in symptoms followed by declines after 6 months. Regarding comorbid problems, there was a main effect of starting ADHD medication on the number of delinquent acts for those who engaged in any delinquency, with those who started medication showing greater increases in delinquency. There was a trend-level medication × condition interaction for adolescent-reported internalizing symptoms. Probing the interaction revealed no condition effects in either group; however, effects were in different directions, which likely accounted for the interaction term. Finally, there was a medication × condition interaction for SU. For those who started medication, there was a condition effect indicating that clients in the integrated condition were more likely to use substances across the follow-up period (B [SE] = 1.12 [0.44]; 95% CI, 0.24-2.0; pseudo-z = 2.57; P = .010; n = 24) than those in the behavioral-only condition.

Table 12. Models Testing Main Effects of Condition and ADHD Medication and Moderating Effects of ADHD Medication on Outcomes.

Table 12

Models Testing Main Effects of Condition and ADHD Medication and Moderating Effects of ADHD Medication on Outcomes.

Discussion

Results of the randomized trial provide only modest experimental evidence that, as hypothesized, integrated treatment (CASH-AA plus MIP) was superior to behavioral-only treatment (CASH-AA only) for 3 of 18 outcomes across multiple domains (ADHD symptoms, co-occurring problems, developmental functioning) at 1-year follow-up, both overall and for specific demographic subgroups. Study findings offer some support for the potential value of including medication decision-making interventions along with academic training interventions for adolescents with ADHD.

To facilitate interpretation of the complex results of this cluster randomized trial, the remainder of the discussion is organized into 3 sections. In section 1, we summarize main outcome findings and subpopulation findings for the client outcome domains: ADHD clinical symptoms, co-occurring clinical problems, developmental functioning (executive functioning and school performance), clinical services use, and ADHD medication use. In section 2, we provide a basic scientific and clinical context for main study findings, attempting to specify how study results contribute to the existing literature on effective interventions for ADHD among adolescents. In section 3, we describe the primary strengths and numerous important limitations of the study.

Section 1: Study Findings

Main Treatment Outcomes

Integrated clients showed greater declines in adolescent-reported inattentive symptoms than did behavioral-only clients. Integrated treatment also outperformed behavioral-only treatment in reducing delinquency for a subgroup of participants: Among teenagers who engaged in any delinquent acts during follow-up, those who received integrated care showed larger decreases in this co-occurring problem. However, integrated care did not outperform behavioral-only care on adolescent-reported symptoms of hyperactivity and impulsivity. It also did not prove superior on any caregiver-reported symptoms, that is, on either ADHD symptoms (inattention/disorganization, hyperactivity/impulsivity) or co-occurring problems (internalizing symptoms, externalizing symptoms, delinquent acts). Also, contrary to expectations, there were no main treatment effects on service use or ADHD medication use. On balance, integrated treatment outperformed behavioral-only treatment for a small subset of main clinical outcomes, and for no service use outcomes at all.

Subpopulation Considerations

According to adolescent reports, integrated treatment was superior to behavioral-only treatment in reducing both inattention and hyperactivity among boys only. The pattern of effects suggested that the conditions produced comparable gains at 6-month follow-up, but thereafter, the behavioral-only condition showed a return toward baseline levels of inattention and hyperactivity. However, outcomes were mixed among subgroups of teens who did, and did not, use illegal substances. Among teens not using substances, there were greater initial declines in adolescent-reported externalizing symptoms for clients in the integrated condition, a decline that leveled off over time. Among substance-using teens, the integrated condition showed greater increases in adolescent-reported externalizing. Also, behavioral-only clients showed more improvement in caregiver-reported hyperactivity symptoms compared with integrated clients. Patterns of data that related to differences in treatment effects between racial/ethnic subgroups were too small and inconsistent across various co-occurring problems to support confident interpretation. Also, integrated care produced improvements in both self-regulation and minutes spent doing homework among girls but not boys. There were contrasting effects of age: Integrated care produced greater gains in academic self-efficacy for older teens but lesser gains for younger teens.

Regarding service use, among teens using substances those in integrated care attended more behavioral therapy sessions than those in behavioral-only care. Regarding ADHD medication use, a significant treatment effect on medication use was observed for 1 key subgroup: Among older adolescents, those in integrated care were more likely to use ADHD medication across the follow-up period than those in behavioral-only care, a plausible outcome given that MIP is designed to foster increased medication decision-making, and older adolescents are developmentally more active in self-care than younger adolescents (see “Section 2: Family-Based Medication Decision Making: MIP”).

Finally, for exploratory purposes, we examined ADHD medication use as a predictor of other treatment outcomes. Overall, the small subgroup of participants who initiated medication subsequent to baseline (n = 24) showed greater increases in delinquent acts than those who did not initiate use (n = 121). Note that this is a post hoc correlational effect only, observed in a population in which randomization was preserved, and it therefore does not indicate that initiating medication was a cause of increased delinquency. Also, among the subgroup of participants who initiated medication, there were findings for 2 outcomes: (1) Integrated participants showed greater initial decrease in caregiver-reported hyperactivity followed by return toward baseline levels, whereas behavioral-only participants showed greater initial increase in caregiver-reported hyperactivity followed by return toward baseline; and (2) behavioral-only participants were more likely to report no SU during follow-up than were integrated cases. Note that these exploratory findings are difficult to interpret with confidence because (1) they involve comparisons between selected, nonrandomized groups, which opens the door to between-group baseline differences as well as third-variable influences on observed effects; (2) analyses on the subgroup of participants who initiated medication contain a very small sample size; and (3) the overall pattern of results is not convincingly coherent.

Section 2: Main Study Contributions

Family-Based Medication Decision-Making: MIP

The primary contribution of this randomized effectiveness trial is modest evidence that medication decision-making interventions, embodied in the MIP, appeared to facilitate improvement in some clinical and developmental outcomes among adolescents with ADHD enrolled in routine behavioral care. Some positive effects were shown for all teens (ie, inattentive symptoms, delinquency), whereas others appeared to be strongest for boys only (ie, hyperactivity symptoms), girls only (ie, self-regulation, time devoted to homework), or teens not identified as substance users (ie, externalizing symptoms). Additional research that focuses more specifically on samples of these and other key demographic and clinical subgroups is needed to confirm and extend findings from the current study regarding MIP effects. Population-specific research of this kind, focused on more homogeneous clinical groups, is especially important for understanding how to improve treatment delivery and treatment outcomes in traditionally underserved subgroups.

Results showed that medication decision-making interventions were associated with increased ADHD medication use, albeit for older teens only. This is not entirely surprising given that older teens are more developmentally primed for active and autonomous participation in decision-making activities of all kinds, including use of medications. However, contrary to expectations, we found that integrated care did not increase ADHD medication initiation among adolescents who were not taking medication at baseline. Thus, the evidence of integrated treatment effects on clinical outcomes was only partially complemented by effects on medication outcomes. It is important to consider that integrated care may have influenced gains in targeted clinical outcomes by means other than increasing ADHD medication prescriptions or adherence. As described earlier, MIP contains an education module that includes tool-guided instruction for both adolescents and caregivers regarding ADHD symptoms and typical course, stigma concerns, and related executive functioning issues; personalized assessment of ADHD-related character strengths and weaknesses; family-focused interventions aimed at diluting negative labels for ADHD-related behaviors and restructuring family interactions toward more positive and proactive solutions to ADHD-related problems; and increased attention to medication-related issues within behavioral therapy sessions. Any and all of these MIP intervention foci may have contributed to the clinical gains shown in the integrated care condition.

As a complement to these clinical and medication outcomes, treatment implementation data supplied by therapists suggested that therapists in the integrated condition devoted marginally more time to discussing ADHD medication issues in behavioral sessions. MIP is designed to increase evidence-informed and person-centered collaboration between families and providers about the suitability of ADHD medication for any given teen, that is, to increase the family's knowledge of the availability and relevance of the medication option, rather than to increase medication uptake per se. In this vein, more research is needed on the complex decision-making calculus used by adolescents and families when deliberating about ADHD medications, as well as how such decisions are ultimately influenced by a myriad of demographic, motivational, and treatment context characteristics.

The presence of co-occurring SU problems appeared to inhibit some potential benefits of integrated treatment. Whereas integrated care produced improvements in externalizing symptoms among teens not using substances, this was not true for teens who were using substances. However, teens using substances in integrated care did attend more behavioral therapy sessions than teens using substances in behavioral-only care. Stronger retention in behavioral health services is generally considered a positive use outcome among difficult-to-treat adolescent populations. There was no evidence that SU status was related to ADHD medication initiation or use in this sample.

The modest evidence supporting the effectiveness of MIP for inattention symptoms and delinquent acts is reinforced by the rigorous features of the study design. The combined CASH-AA plus MIP condition was experimentally compared not with treatment as usual, but rather with a CASH-AA condition that received identical levels of training, consultation, and technical assistance from extramural experts. Also, the study design emphasized ecological validity and generalizability: Study therapists were all usual care clinicians operating with no changes to their routine caseloads or work conditions, beyond the modest addition of attending a few 90-minute protocol introduction workshops followed by monthly 60-minute consultation meetings on protocol delivery.

Enhancing the use and effectiveness of medication decision-making interventions for ADHD can be considered critical to improving quality care standards for adolescent behavioral health. Medication is an empirically supported option for treating ADHD in adolescents3 and is considered an essential component of effective treatment planning for this population.73 Available empirical data indicate that ADHD medication can have substantive effects in multiple domains for adolescents.1 To reduce the medication quality-of-care gap for adolescents with ADHD, it is essential to develop innovative clinical procedures designed to support the integration of ADHD medication into everyday behavioral care.74 Specifically, procedures are needed to (1) increase opportunities for families to make informed decisions about ADHD medication acceptance, and (2) support family participation and compliance in medication regimens.12 MIP improved 3 of the 18 main outcomes we tested, a step in this direction.

Academic Training Interventions: CASH-AA

The current study is among the first to include academic training interventions for ADHD in an outpatient setting, and perhaps the first to feature community therapists practicing in routine care within both mental health and SU treatment settings. To close the gap in available services for ADHD among adolescents, it is critical to extend the clinical knowledge gained about training interventions in school settings to non-school settings where teens often present with behavioral disorders needing clinical intervention (eg, specialty behavioral care, primary medical care, social services). Other school-based75,76 and clinic-based77 studies of academic training have documented multidomain effects for adolescents with ADHD. Further work on translating effective academic training protocols from school to clinic settings should be a top priority for developers of youth ADHD interventions.78

Overall Clinical Implications

Increasing high-fidelity delivery of research-based behavioral interventions for ADHD is important for improving quality care standards for adolescent behavioral health. MIP showed some effects in addressing some ADHD symptoms and co-occurring problems, and youth with SU problems benefited along with peers who did not use substances. Certainly, our study findings are a first foray in testing the utility of these protocols in the hands of frontline clinicians. Such tools are especially needed to buttress integrated health care models that foster a collaborative approach to combining behavioral and pharmacologic interventions, and moreover, to empower behavioral therapists to play a lead role in cultivating integrated services.79 Further validation and articulation of academic training and medication decision-making interventions in usual care, the study protocols, and other interventions like them (eg, Sibley et al77), will strengthen our capacity to support the clinical workforce in achieving best outcomes for this prevalent and difficult-to-treat population.

Section 3: Strengths and Limitations

A main strength of the study was high external validity that affirms the generalizability of findings to real-world practice: Community therapists delivered the treatment protocols in everyday settings, and adolescents with ADHD from diverse backgrounds were enrolled in usual care, with psychiatric comorbidity the norm. Study therapists within each site were randomly assigned to study condition, which strengthened internal validity and muted therapist and site effects that might otherwise confound study results. Both adolescent and caregiver reports were used to gauge clinical progress, and ITT analyses were used for all main outcomes. Assessment of organizational culture and climate indicated that study sites were broadly representative of the national behavioral health treatment system.

Numerous limitations warrant mention. There was no treatment-as-usual comparison group, which limits conclusions that can be drawn about differences between the 2 intervention conditions (ie, CASH-AA plus MIP, and CASH-AA only) and usual practice. The study occurred in the New York City metropolitan area, thus imposing accompanying geographic limits to generalizability. The number of participating sites was too small to control for site clustering effects via random-effects analyses. The study was not adequately powered to support post hoc inspection of individual site effects using similarly rigorous analyses; thus, it is not known whether any of the partnering treatment sites performed at a significantly higher or lower level than others. Participating therapists at each site were self-selected, and although at most sites those volunteering to participate constituted most available clinical staff, they may not have been representative of all staff at a given site. The 2:1 randomization ratio was not, strictly speaking, achieved due to initially randomized therapists being excluded from the study because they were never assigned an eligible study case (n = 33), as well as the need to assign a small subset of therapists nonrandomly to study condition to maintain critical mass for group-based protocol consultation meetings.

Also, in the absence of a no-treatment control group, the degree to which the research interview process itself, independently of treatment effects, impacted assessment of client outcomes cannot be estimated, although such impacts are presumed equally distributed across study conditions. There were also key assessment limitations. Indices of client outcomes were collected from adolescents and caregivers only, to the exclusion of outcome data collected from school and clinical professionals who provide important and respectively unique perspectives on the behavioral functioning of youth with ADHD. Although pharmacologic studies often assess medication use via documentation of prescriptions filled and/or monthly pill counts by physicians (vs patient self-report), these more rigorous assessment methods were beyond the resources of this study.

Another limitation pertains to the conflicting reports of treatment fidelity submitted by study therapists (using post-session self-reports) vs observational coders (who reviewed session audio recordings). On the one hand, both sources concurred that there was no between-condition difference in delivery of CASH-AA protocol elements. This finding was as predicted and indicates experimental fidelity, given that both conditions were expected to implement the CASH-AA protocol in equal measure. Also indicative of experimental fidelity, therapists in the integrated condition (CASH-AA plus MIP) reported delivering a greater amount of MIP elements than those assigned to the CASH-AA intervention alone, and devoting more session time to discussing ADHD issues and ADHD medication, than did their counterparts in the behavioral-only (CASH-AA only) condition. However, coders did not report strong adherence to the MIP in the integrated condition; rather, they observed no significant differences between conditions in MIP delivery, discussion of ADHD issues, or discussion of ADHD medication. To be sure, it is typical to find lack of concordance between therapist self-report and observational coding of delivery of model-specific treatment techniques for all kinds of behavioral interventions. Studies attempting to show concordance between therapist self-ratings and observer ratings of fidelity have mostly produced disappointing results, casting doubt on whether therapists can reliably rate their own performance.80 This includes research-trained clinicians delivering manualized treatment protocols81,82 as well as frontline clinicians delivering native interventions in routine care.32,83

The absence of observational coder support for expected MIP adherence evidence calls into question the MIP “dosage strength” received by participants enrolled in the integrated condition. It is possible that having a more structured (less flexible) protocol format, in which aspects of the MIP were prescribed for delivery in specified sessions and for specified amounts of session time, would have resulted in greater fidelity to the model and greater differentiation between conditions. It is also not known whether increasing protocol structure in this manner would have exerted a positive, negative, or neutral influence on therapist motivation to implement the study protocols. Finally, it is difficult to determine, under the conditions of this effectiveness trial in which both study protocols were flexibly implemented, whether each condition should be respectively characterized as having received a strong, adequate, or weak dose of each protocol. Additional research on dose-response effects, in which variation in the extensiveness of protocol implementation is correlated with variation in client outcomes, is needed to shed further empirical light on this issue.

Finally, an important caveat pertains to the nomenclature of the integrated condition. This condition was named “integrated” due to its emphasis on increasing the integration of pharmacologic interventions into behavioral care for adolescents with ADHD. However, the MIP is, itself, a behavioral intervention. Thus, whereas MIP is intended to facilitate greater integration of medication and behavioral treatments, the experimental design did not manipulate or otherwise assign ADHD medication status to any participant, nor did study procedures introduce inclusion criteria or service demands related to medication status of any kind. From this perspective, the “integrated” condition might be more accurately described as the “intent to integrate” condition. For certain, it should not be regarded as a bona fide “combined” treatment group, which refers to treatment packages whereby pharmacologic and behavioral interventions are paired by design,84 such that every participant in the condition is expected to receive medication.

Conclusions

This study marks a promising beginning to the study of methods to improve the effectiveness of family-based medication decision-making interventions. For MIP, when combined with academic training interventions in routine behavioral care, significant additive main effects were found for 3 of the 18 main outcomes measured and for various subgroups of adolescents across some of the many clinical, developmental, and medication outcomes measured. Despite the inconsistency of the findings across multiple outcome measures, outpatient behavioral health care providers who treat adolescents with ADHD, including those with co-occurring disorders, might consider implementing both evidence-based academic support interventions and family-based medication decision-making interventions to achieve the best outcomes for this difficult-to-treat population.6

References

1.
Sibley MH, Kuriyan AB, Evans SW, Waxmonsky JG, Smith BH. Pharmacological and psychosocial treatments for adolescents with ADHD: an updated systematic review of the literature. Clin Psychol Rev. 2014;34(3):218-232. [PubMed: 24632046]
2.
Evans SW, Owens JS, Wymbs BT, Ray AR. Evidence-based psychosocial treatments for children and adolescents with attention deficit/hyperactivity disorder. J Clin Child Adolesc Psychol. 2018;47(2):157-198. [PubMed: 29257898]
3.
Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007-1022. [PMC free article: PMC4500647] [PubMed: 22003063]
4.
Evans SW, Owens JS, Bunford N. Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol. 2014;43(4):527-551. [PMC free article: PMC4025987] [PubMed: 24245813]
5.
Langberg JM, Becker SP. Does long-term medication use improve the academic outcomes of youth with attention-deficit/hyperactivity disorder? Clin Child Fam Psychol Rev. 2012;15(3):215-233. [PubMed: 22678357]
6.
Hogue A, Evans SW, Levin FR. A clinician's guide to co-occurring ADHD among adolescent substance users: comorbidity, neurodevelopmental risk, and evidence-based treatment options. J Child Adolesc Subst Abuse. 2017;26(4):277-292. [PMC free article: PMC6392461] [PubMed: 30828239]
7.
Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry. 2013;70(7):740-749. [PMC free article: PMC6688478] [PubMed: 23754458]
8.
Molina BS, Hinshaw SP, Arnold LE, et al. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD)(MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 2013;52(3):250-263. [PMC free article: PMC3589108] [PubMed: 23452682]
9.
Bukstein OG, Cornelius J. Psychopharmacology of adolescents with substance use disorders: using diagnostic-specific treatments. In: Liddle HA, Rowe CL, eds. Adolescent Substance Abuse: Research and Clinical Advances. Cambridge University Press; 2006:241-263.
10.
Yeh M, Aarons GA, Ho J, et al. Parental etiological explanations and longitudinal medication use for youths with attention deficit hyperactivity disorder. Adm Policy Ment Health. 2014;41(3):401-409. [PMC free article: PMC3864543] [PubMed: 23504264]
11.
Murphy K. Psychosocial treatments for ADHD in teens and adults: a practice-friendly review. J Clin Psychol. 2005;61(5):607-619. [PubMed: 15723366]
12.
Davis CC, Claudius M, Palinkas LA, Wong JB, Leslie LK. Putting families in the center: family perspectives on decision making and ADHD and implications for ADHD care. J Atten Disord. 2012;16(8):675-684. [PubMed: 21976032]
13.
Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361-1367. [PMC free article: PMC3445676] [PubMed: 22618581]
14.
Friedrichs A, Spies M, Härter M, Buchholz A. Patient preferences and shared decision making in the treatment of substance use disorders: a systematic review of the literature. PLoS One. 2016;11(1):e0145817. doi:10.1371/journal.pone.0145817 [PMC free article: PMC4701396] [PubMed: 26731679] [CrossRef]
15.
Weisz JR, Chorpita BF, Frye A, et al. Youth top problems: using idiographic, consumer-guided assessment to identify treatment needs and to track change during psychotherapy. J Consult Clin Psychol. 2011;79(3):369-380. [PubMed: 21500888]
16.
Joosten EAG, DeFuentes-Merillas L, De Weert GH, Sensky T, Van Der Staak CPF, de Jong CA. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom. 2008;77(4):219-226. [PubMed: 18418028]
17.
Lin GA, Fagerlin A. Shared decision making: state of the science. Circ Cardiovasc Qual Outcomes. 2014;7(2):328-334. [PubMed: 24496297]
18.
Langer DA, Jensen-Doss A. Shared decision-making in youth mental health care: using the evidence to plan treatments collaboratively. J Clin Child Adolesc Psychol. 2018;47(5):821-831. [PMC free article: PMC5457360] [PubMed: 27911081]
19.
Durand MA, Witt J, Joseph-Williams N, et al. Minimum standards for the certification of patient decision support interventions: feasibility and application. Patient Educ Couns. 2015;98(4):462-468. [PubMed: 25577469]
20.
Légaré F, Kearing S, Clay K, et al. Are you SURE?: assessing patient decisional conflict with a 4-item screening test. Can Fam Physician. 2010;56(8):e308-e314. https://www​.ncbi.nlm​.nih.gov/pmc/articles/PMC2920798/ [PMC free article: PMC2920798] [PubMed: 20705870]
21.
Hogue A, Bobek M, Evans SW. Changing academic support in the home for adolescents with attention-deficit/hyperactivity disorder: a family-based clinical protocol for improving school performance. Cogn Behav Pract. 2016;23(1):14-20. [PMC free article: PMC8184116] [PubMed: 34103882]
22.
Hogue A, Bobek M, Tau GZ, Levin FR. Clinical strategies for integrating medication interventions into behavioral treatment for adolescent ADHD: the medication integration protocol. Child Fam Behav Ther. 2014;36(4):280-304. [PMC free article: PMC4258514] [PubMed: 25505817]
23.
Hogue A, Lichvar E, Bobek M. Pilot evaluation of the medication integration protocol for adolescents with ADHD in behavioral care: treatment fidelity, acceptability, and utilization. J Emot Behav Disord. 2016;24(4):223-234. [PMC free article: PMC8188877] [PubMed: 34113069]
24.
Ball SA, Martino S, Nich C, et al. Site matters: multisite randomized trial of motivational enhancement therapy in community drug abuse clinics. J Consult Clin Psychol. 2007;75(4):556-567. [PMC free article: PMC2148493] [PubMed: 17663610]
25.
Swanson J, Nolan W, Pelham W. Swanson, Nolan and Pelham Teacher and Parent Rating Scale (Snap-IV). 2013. Accessed October 5, 2020. https://www​.mcpap.com/pdf/SNAPIV.pdf
26.
Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(20):22-33. [PubMed: 9881538]
27.
Lecrubier Y, Sheehan DV, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry. 1997;12(5):224-231.
28.
Sheehan DV, Lecrubier Y, Sheehan KH, et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry. 1997;12(5):232-241.
29.
Achenbach TM. Manual for the Child Behavior Checklist/4-18 and 1991 Profile. Department of Psychiatry, University of Vermont; 1991.
30.
Achenbach TM. Manual for the Youth Self-report and 1991 Profile. Department of Psychiatry, University of Vermont; 1991.
31.
Achenbach TM, Rescorla LA. Manual for the Achenbach System of Empirically Based Assessment School-Age Forms Profiles. Aseba; 2001.
32.
Hogue A, Dauber S, Henderson CE, et al. Randomized trial of family therapy versus nonfamily treatment for adolescent behavior problems in usual care. J Clin Child Adolesc Psychol. 2015;44(6):954-969. [PMC free article: PMC4465884] [PubMed: 25496283]
33.
Kerns CM, Renno P, Kendall PC, Wood JJ, Storch EA. Anxiety Disorders Interview Schedule-Autism Addendum: reliability and validity in children with autism spectrum disorder. J Clin Child Adolesc Psychol. 2017;46(1):88-100. [PMC free article: PMC5441235] [PubMed: 27925775]
34.
Baxter EE, Alexander PC, Kraus DR, Bentley JH, Boswell JF, Castonguay LG. Concurrent validation of the Treatment Outcome Package (TOP) for children and adolescents. J Child Fam Stud. 2016;25(8):2415-2422.
35.
Elliott DS, Ageton SS, Huizinga D, Knowles BA, Cantor RJ. The Prevalence and Incidence of Delinquent Behavior: 1976-1980. National Youth Survey Report No. 26. Behavioral Research Institute; 1983.
36.
Huizinga D, Elliott DS. Self-Report Measures of Delinquency and Crime: Methodological Issues and Comparative Findings. Behavioral Research Institute; 1983.
37.
Henggeler SW. Delinquency in Adolescence. Sage Publications; 1989.
38.
Huizinga D, Elliot DS. Juvenile offenders: prevalence, offender incidence, and arrest rates by race. Crime Delinq. 1987;33(2):206-223.
39.
Meyers K, McLellan AT, Jaeger JL, Pettinati HM. The development of the Comprehensive Addiction Severity Index for Adolescents (CASI-A): an interview for assessing multiple problems of adolescents. J Subst Abuse Treat. 1995;12(3):181-193. [PubMed: 7474026]
40.
Meyers K, Hagan TA, Zanis D, et al. Critical issues in adolescent substance use assessment. Drug Alcohol Depend. 1999;55(3):235-246. [PubMed: 10428364]
41.
Gioia G, Isquith P, Guy S, Kenworthy L. Behavior Rating Inventory of Executive Function. Psychological Assessment Resources; 2000.
42.
McCandless S, O'Laughlin L. The clinical utility of the Behavior Rating Inventory of Executive Function (BRIEF) in the diagnosis of ADHD. J Atten Disord. 2007;10(4):381-389. [PubMed: 17449837]
43.
Mares D, McLuckie A, Schwartz M, Saini M. Executive function impairments in children with attention-deficit hyperactivity disorder: do they differ between school and home environments? Can J Psychiatry. 2007;52(8):527-534. [PubMed: 17955916]
44.
Gioia G, Isquith P, Retzlaff P, Espy K. Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function (BRIEF) in a clinical sample. Child Neuropsychol. 2002;8(4):249-257. [PubMed: 12759822]
45.
Thomas SE, Deas D, Grindlinger DR. Gender differences in dependence symptoms and psychiatric severity in adolescents with substance use disorders. J Child Adolesc Subst Abuse. 2003;12(4):19-34.
46.
Pintrich PR, Smith DA, Garcia T, McKeachie WJ. Reliability and predictive validity of the Motivated Strategies for Learning Questionnaire (MSLQ). Educ Psychol Meas. 1993;53(3):801-813.
47.
Anesko KM, Schoiock G, Ramirez R, Levine FM. The Homework Problem Checklist: assessing children's homework difficulties. Behav Assess. 1987;9(2):179-185.
48.
Power TJ, Werba BE, Watkins MW, Angelucci JG, Eiraldi RB. Patterns of parent-reported homework problems among ADHD-referred and non-referred children. Sch Psychol Q. 2006;21(1):13.
49.
Hoagwood K, Horwitz S, Stiffman A, et al. Concordance between parent reports of children's mental health services and service records: the Services Assessment for Children and Adolescents (SACA). J Child Fam Stud 2000;9(3):315-331.
50.
Stiffman AR, Hadley-Ives E, Doré P, et al. Youths' access to mental health services: the role of providers' training, resource connectivity, and assessment of need. Ment Health Serv Res. 2000;2(3):141-154. [PubMed: 11256723]
51.
Snijders TAB. Power and sample size in multilevel linear models. In: Everitt B, Howell D, eds. Encyclopedia of Statistics in Behavioral Science. Wiley; 2005.
52.
Murray DM. Design and Analysis of Group-Randomized Trials. Monographs in Epidemiology and Biostatistics, Vol 29. Oxford University Press; 1998.
53.
Raudenbush S, Spybrook J, Liu X, Congdon R. Optimal Design for Longitudinal and Multilevel Research: Documentation for the “Optimal Design” Software. University of Michigan; 2005.
54.
Borenstein M, Rothstein H, Cohen J. Power and Precision [software program]. Biostat; 1997. Accessed October 5, 2020. https://www​.power-analysis​.com/pdfs/power_precision_manual​.pdf
55.
Feng Z, Diehr P, Yasui Y, Evans B, Beresford S, Koepsell TD. Explaining community-level variance in group randomized trials. Stat Med. 1999;18(5):539-556. [PubMed: 10209810]
56.
Scheier LM, Griffin KW, Doyle MM, Botvin, GJ. Estimates of intragroup dependence for drug use and skill measures in school-based drug abuse prevention trials: an empirical study of three independent samples. Health Educ Behav. 2002;29(1):85-103. [PubMed: 11822555]
57.
Slymen DJ, Hovell MF. Cluster versus individual randomization in adolescent tobacco and alcohol studies: illustrations for design decisions. Int J Epidemiol. 1997;26(4):765-771. [PubMed: 9279608]
58.
Raudenbush S. Statistical analysis and optimal design for cluster randomized trials. Psychol Methods. 1997;2(2):173-185. [PubMed: 10937329]
59.
Zucker DM. An analysis of variance pitfall: the fixed effects analysis in a nested design. Educ Psychol Meas. 1990;50:731-738.
60.
Asparouhov T. Sampling weights in latent variable modeling. Struct Equ Modeling. 2005;12(3):411-434.
61.
Kreft I, de Leeuw J. Introducing Multilevel Modeling. Sage Publications; 1998.
62.
Feaster D, Robbins M, Horigan V, Szapocznik J. Brief strategic family therapy: statistical design of a multi-site effectiveness trial for adolescent drug abuse treatment. Paper presented at: Annual Conference of the College on Problems of Drug Dependence; June 14-19, 2003; Bal Harbour, FL.
63.
Newsom JT. Longitudinal Structural Equation Modeling: A Comprehensive Introduction. Routledge; 2015.
64.
Singer JD, Willett JB. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. Oxford University Press; 2003.
65.
Duncan TE, Duncan SC, Strycker LA. An Introduction to Latent Variable Growth Curve Modeling: Concepts, Issues, and Applications. Erlbaum; 2006.
66.
Muthén LK, Muthén B. Mplus User's Guide. 7th ed. Muthén & Muthén; 2010.
67.
Feingold A. Effect sizes for growth-modeling analysis for controlled clinical trials in the same metric as for classical analysis. Psychol Methods. 2009;14(1):43-53. [PMC free article: PMC2712654] [PubMed: 19271847]
68.
Brown EC, Catalano RF, Fleming CB, Haggerty KP, Abbott RD. Adolescent substance use outcomes in the Raising Healthy Children project: a two-part latent growth curve analysis. J Consult Clin Psychol. 2005;73(4):699. [PubMed: 16173857]
69.
Diggle P, Heagerty P, Liang K, Zeger S. Analysis of Longitudinal Data. 2nd ed. Oxford University Press; 2002.
70.
Herman KC, Ostrander R, Walkup JT, Silva SG, March JS. Empirically derived subtypes of adolescent depression: latent profile analysis of co-occurring symptoms in the Treatment for Adolescents with Depression Study (TADS). J Consult Clin Psychol. 2007;75(5):716-728. [PubMed: 17907854]
71.
Little R, Rubin D. Statistical Analysis with Missing Data. Wiley; 1987.
72.
Schafer JL, Graham J. Missing data: our view of the state of the art. Psychol Methods. 2002;7(2):147-177. [PubMed: 12090408]
73.
Collins LM, Schafer JL, Kam CM. A comparison of inclusive and restrictive strategies in modern missing data procedures. Psychol Methods. 2001;6(4):330-351. [PubMed: 11778676]
74.
Obioha O, Adesman A. Pearls, perils, and pitfalls in the assessment and treatment of attention-deficit/hyperactivity disorder in adolescents. Curr Opin Pediatr. 2014;26(1):119-129. [PubMed: 24370490]
75.
Evans SW, Langberg JM, Schultz BK, et al. Evaluation of a school-based treatment program for young adolescents with ADHD. J Consult Clin Psychol. 2016;84(1):15-30. [PubMed: 26501496]
76.
Langberg JM, Dvorsky MR, Molitor SJ, et al. Overcoming the research-to-practice gap: a randomized trial with two brief homework and organization interventions for students with ADHD as implemented by school mental health providers. J Consult Clin Psychol. 2018;86(1):39-55. [PubMed: 29172596]
77.
Sibley MH, Graziano PA, Kuriyan AB, et al. Parent-teen behavior therapy + motivational interviewing for adolescents with ADHD. J Consult Clin Psychol. 2016;84(8):699-712. [PMC free article: PMC4949080] [PubMed: 27077693]
78.
Ciesielski HA, Tamm L, Vaughn AJ, Cyran JE, Epstein JN. Academic skills groups for middle school children with ADHD in the outpatient mental health setting: an open trial. J Atten Disord. 2019;23(4):409-417. [PMC free article: PMC4626438] [PubMed: 25926629]
79.
Robiner WN, Tumlin TR, Tompkins TL. Psychologists and medications in the era of interprofessional care: collaboration is less problematic and costly than prescribing. Clin Psychol Sci Pract. 2013;20(4):489-507.
80.
Wain RM, Kutner BA, Smith JL, et al. Self-report after randomly assigned supervision does not predict ability to practice motivational interviewing. J Subst Abuse Treat. 2015;57:96-101. [PMC free article: PMC4560973] [PubMed: 25963775]
81.
Carroll KM, Nich C, Rounsaville BJ. Utility of therapist session checklists to monitor delivery of coping skills treatment for cocaine abusers. Psychother Res. 1998;8(3):307-320.
82.
Martino S, Ball S, Nich C, Frankforter TL, Carroll KM. Correspondence of motivational enhancement treatment integrity ratings among therapists, supervisors, and observers. Psychother Res. 2009;19(2):181-193. [PMC free article: PMC2782382] [PubMed: 19396649]
83.
Hurlburt MS, Garland AF, Nguyen K, Brookman-Frazee L. Child and family therapy process: concordance of therapist and observational perspectives. Adm Policy Ment Health. 2010;37(3):230-244. [PMC free article: PMC2877358] [PubMed: 19902347]
84.
Hogue A, Henderson CE, Becker SJ, Knight DK. Evidence base on outpatient behavioral treatments for adolescent substance use, 2014-2017: outcomes, treatment delivery, and promising horizons. J Clin Child Adolesc Psychol. 2018;47(4):499-526. [PMC free article: PMC7192024] [PubMed: 29893607]

Acknowledgment

Research reported in this report was funded through a Patient-Centered Outcomes Research Institute® (PCORI®) Award (#CER-1403-13704). Further information available at: https://www.pcori.org/research-results/2014/assessing-support-medicine-decision-making-youth-adhd-who-receive-therapy

Appendices

Appendix A.

Treatment Protocol Descriptions (PDF, 175K)

Appendix B.

Therapist Focus Groups (PDF, 242K)

Institution Receiving Award: Center on Addiction (formerly CASAColumbia)
PCORI ID: CER-1403-13704
ClinicalTrials.gov ID: NCT02420990

Suggested citation:

Hogue A, Fisher JH, Dauber S. (2020). Assessing Support for Medicine Decision Making for Youth with ADHD Who Receive Therapy. Patient-Centered Outcomes Research Institute (PCORI). https://doi.org/10.25302/09.2020.CER.140313704

Disclaimer

The [views, statements, opinions] presented in this report are solely the responsibility of the author(s) and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute® (PCORI®), its Board of Governors or Methodology Committee.

Copyright © 2020. Center on Addiction. All Rights Reserved.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License which permits noncommercial use and distribution provided the original author(s) and source are credited. (See https://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK594605PMID: 37672618DOI: 10.25302/09.2020.CER.140313704

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.6M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...